var title_f18_5_18512="2D TTE 4-chamber descending thoracic aorta";
var content_f18_5_18512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from a modified four-chamber view showing the descending thoracic aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 203px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thoracic or descending aorta (T Ao) can be imaged from the apical two and four chamber view. Posterior angulation (panel B) shows the T Ao in its short axis, located below the left atrium (LA). Anterior angulation in four chamber view (panel A) shows the origin of aortic root (Ao).",
"    <div class=\"footnotes\">",
"     RA: right atrium; LA: left atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18512=[""].join("\n");
var outline_f18_5_18512=null;
var title_f18_5_18513="Invasive aspergillosis CT";
var content_f18_5_18513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Invasive aspergillosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography (CT) scan of an immunosuppressed patient with fever, hypoxemia, and a nonresolving pneumonia. Invasive aspergillosis was ultimately diagnosed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alan Fein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18513=[""].join("\n");
var outline_f18_5_18513=null;
var title_f18_5_18514="Contents: Primary care gastroenterology";
var content_f18_5_18514=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care gastroenterology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care gastroenterology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acid peptic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/22/30055\">",
"           Acute and chronic gastritis due to Helicobacter pylori",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/4/27720\">",
"           Approach to the patient with dyspepsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/40/44679\">",
"           Association between Helicobacter pylori infection and duodenal ulcer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/16/43271\">",
"           Bacteriology and epidemiology of Helicobacter pylori infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/30/31205\">",
"           Classification and diagnosis of gastritis and gastropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/18/13609\">",
"           Clinical manifestations of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/21/24919\">",
"           Diagnosis of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/42/19113\">",
"           Epidemiology and etiology of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/28/35272\">",
"           Functional dyspepsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/59/37817\">",
"           Indications and diagnostic tests for Helicobacter pylori infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/10/12455\">",
"           Management of duodenal ulcers in patients infected with Helicobacter pylori",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38393\">",
"           NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/21/40282\">",
"           Overview of the complications of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/18/42281\">",
"           Overview of the natural history and treatment of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/15/24826\">",
"           Overview of the treatment of bleeding peptic ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/44/4809\">",
"           Pathophysiology of and immune response to Helicobacter pylori infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/47/13049\">",
"           Pharmacology of antiulcer medications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/61/16345\">",
"           Refractory or recurrent peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/57/33688\">",
"           Role of surgery in the management of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/5/40025\">",
"           Surgical management of complications of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/32/23049\">",
"           Treatment regimens for Helicobacter pylori",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/0/19466\">",
"           Unusual causes of peptic ulcer disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Biliary and pancreatic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/37/6742\">",
"           Acalculous cholecystitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/13/24790\">",
"           Acute cholangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/8/10374\">",
"           Approach to the patient with incidental gallstones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/57/7065\">",
"           Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/5/20569\">",
"           Clinical manifestations and diagnosis of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/13/30935\">",
"           Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/40/41610\">",
"           Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/50/42790\">",
"           Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/16/6408\">",
"           Dissolution therapy for the treatment of gallstones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/24/4489\">",
"           Epidemiology of and risk factors for gallstones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/41/39575\">",
"           Etiology and pathogenesis of chronic pancreatitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/61/14297\">",
"           Etiology of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/19/34105\">",
"           Overview of the treatment of primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/33/29208\">",
"           Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/15/14582\">",
"           Patient selection for the nonsurgical treatment of gallstone disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/29/44504\">",
"           Predicting the severity of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/19/23863\">",
"           Pruritus associated with cholestasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/9/15511\">",
"           Treatment of acute cholecystitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/40/31369\">",
"           Treatment of chronic pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/8/41097\">",
"           Treatment of primary sclerosing cholangitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Esophageal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/56/15240\">",
"           Chest pain of esophageal origin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/26/14759\">",
"           Clinical manifestations and diagnosis of achalasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/41/22168\">",
"           Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/51/19253\">",
"           Complications of gastroesophageal reflux in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/8/1161\">",
"           Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/17/12569\">",
"           Evaluation of dysphagia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/19/21814\">",
"           Globus sensation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/19/43317\">",
"           Mallory-Weiss syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/61/35802\">",
"           Management of Barrett's esophagus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/53/42840\">",
"           Medical management of gastroesophageal reflux disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/13/37078\">",
"           Medication-induced esophagitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/39/18039\">",
"           Overview of the treatment of achalasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/38/13928\">",
"           Pathophysiology of reflux esophagitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/57/42905\">",
"           Surgical management of gastroesophageal reflux in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29512\">",
"           Zenker's diverticulum",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal bleeding",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/55/28538\">",
"           Approach to acute upper gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/63/8184\">",
"           Approach to minimal bright red bleeding per rectum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/7/30841\">",
"           Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/49/38679\">",
"           Colonic diverticular bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/6/7272\">",
"           Etiology of lower gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/4/11336\">",
"           Evaluation of occult gastrointestinal bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/56/1928\">",
"           General principles of the management of variceal hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/23/12664\">",
"           Major causes of upper gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/60/21446\">",
"           Prediction of variceal hemorrhage in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/49/27418\">",
"           Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/56/41865\">",
"           Uncommon causes of upper gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/63/8184\">",
"           Approach to minimal bright red bleeding per rectum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/62/32746\">",
"           Approach to the patient with colonic polyps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/36/2634\">",
"           Association between Helicobacter pylori infection and gastrointestinal malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/36/11850\">",
"           Clinical features, diagnosis, and staging of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/43/40633\">",
"           Clinical manifestations and diagnosis of cholangiocarcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/33/17946\">",
"           Clinical manifestations, diagnosis, and staging of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/40/41610\">",
"           Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/7/25722\">",
"           Colorectal cancer surveillance in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/31/18938\">",
"           Epidemiology, clinical features, and types of small bowel neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/54/43881\">",
"           Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/14/16618\">",
"           Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/5/29783\">",
"           Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43063\">",
"           Overview of treatment approaches for hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/12/8391\">",
"           Pathogenesis of Barrett's esophagus and its malignant transformation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/9/3224\">",
"           Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/52/6983\">",
"           Screening and prevention of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37034\">",
"           Screening for colorectal cancer: Strategies in patients at average risk",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/7/5242\">",
"           Acute appendicitis in adults: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/21/44377\">",
"           Acute mesenteric ischemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/24/34181\">",
"           Anal fissure: Clinical manifestations, diagnosis, prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/48/15110\">",
"           Approach to the patient with anal pruritus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/27/33206\">",
"           Chronic mesenteric ischemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/10/14504\">",
"           Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/6/34919\">",
"           Clinical manifestations and diagnosis of colonic diverticular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/59/22455\">",
"           Clinical manifestations and diagnosis of irritable bowel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/0/20490\">",
"           Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/7/11386\">",
"           Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/20/42313\">",
"           Colonic ischemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/17/7450\">",
"           Definition, epidemiology, and risk factors in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/63/36854\">",
"           Epidemiology and pathophysiology of colonic diverticular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/14/25834\">",
"           Fertility, pregnancy, and nursing in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/22/7527\">",
"           Hiatus hernia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/51/6968\">",
"           Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/36/22090\">",
"           Management of mild to moderate ulcerative colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/10/2218\">",
"           Management of patients with a colostomy or ileostomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/15/3319\">",
"           Management of severe ulcerative colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17177\">",
"           Nonselective NSAIDs: Overview of adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/14/5348\">",
"           Overview of hemorrhoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/54/19305\">",
"           Overview of the medical management of mild to moderate Crohn's disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/11/6329\">",
"           Overview of the medical management of severe or refractory Crohn's disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/40/26246\">",
"           Perianal abscess: Clinical manifestations, diagnosis, treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29034\">",
"           Pulmonary complications of inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/53/26453\">",
"           Sigmoid volvulus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/24/41350\">",
"           Skin and eye manifestations of inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/46/14058\">",
"           Small bowel obstruction: Causes and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/38/8807\">",
"           Small bowel obstruction: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/50/4906\">",
"           Surgical management of ulcerative colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/8/13450\">",
"           Treatment of acute diverticulitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/61/6105\">",
"           Treatment of hemorrhoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/14/40169\">",
"           Treatment of irritable bowel syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/17/32025\">",
"           Approach to the adult with acute diarrhea in developed countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/48/26376\">",
"           Clinical presentation and diagnosis of rotavirus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/39/29305\">",
"           Clostridium difficile in adults: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/18/36137\">",
"           Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/29/20954\">",
"           Clostridium difficile in adults: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/29/29145\">",
"           Travelers' diarrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39334\">",
"           Treatment and prevention of Shigella infection in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/1/4121\">",
"           Treatment and prophylaxis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal symptoms",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/1/15384\">",
"           Anal fissure: Medical and surgical management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/63/8184\">",
"           Approach to minimal bright red bleeding per rectum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/55/43897\">",
"           Approach to the adult with chronic diarrhea in developed countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/47/16120\">",
"           Approach to the adult with nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/4/27720\">",
"           Approach to the patient with dyspepsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/48/19208\">",
"           Characteristics of antiemetic drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/14/35048\">",
"           Constipation in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/36/19018\">",
"           Diagnostic approach to abdominal pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/30/16874\">",
"           Differential diagnosis of abdominal pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26345\">",
"           Epidemiology and causes of acute diarrhea in developed countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/22/13673\">",
"           Etiology and evaluation of chronic constipation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/59/22458\">",
"           Fecal incontinence in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/28/35272\">",
"           Functional dyspepsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/24/40323\">",
"           History and physical examination in adults with abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/18/24872\">",
"           Intestinal gas and bloating",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/57/30616\">",
"           Management of chronic constipation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/36/22087\">",
"           Overview of hiccups",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/4/28744\">",
"           Alcoholic hepatitis: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/43/698\">",
"           Alcoholic hepatitis: Natural history and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/18/34090\">",
"           Approach to the patient with abnormal liver biochemical and function tests",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/35/12858\">",
"           Assessing surgical risk in patients with liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/28/36294\">",
"           Clinical aspects of serum bilirubin determination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/42/21162\">",
"           Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/22/34153\">",
"           Clinical manifestations and diagnosis of hepatic encephalopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/63/22521\">",
"           Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/41/23194\">",
"           Diagnostic approach to the patient with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/50/42790\">",
"           Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/57/19353\">",
"           Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5���������-nucleotidase, gamma-glutamyl transpeptidase)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/43/14010\">",
"           Evaluation of adults with ascites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/23/42359\">",
"           Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/15/4346\">",
"           Hepatic encephalopathy in adults: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/10/14506\">",
"           Hepatic encephalopathy: Pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/2/25642\">",
"           Hepatotoxicity due to herbal medications and dietary supplements",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/44/19145\">",
"           Initial therapy of ascites in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/63/21494\">",
"           Liver biochemical tests that detect injury to hepatocytes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/20/5446\">",
"           Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/15/12535\">",
"           Screening for hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/29/24022\">",
"           Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/48/14088\">",
"           Tests used in the diagnosis of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/32/18952\">",
"           Treatment of hereditary hemochromatosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/30/15847\">",
"           Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32980\">",
"           Atypical manifestations of hepatitis A virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/35/21045\">",
"           Characteristics of the hepatitis B virus and pathogenesis of infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/5/29780\">",
"           Characteristics of the hepatitis C virus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/50/31530\">",
"           Clinical manifestations and natural history of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/26/30122\">",
"           Clinical manifestations and natural history of hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/7/2169\">",
"           Epidemiology and transmission of hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/31/4602\">",
"           Epidemiology, transmission, and prevention of hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/38/1641\">",
"           Hepatitis A virus vaccination and postexposure prophylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31690\">",
"           Hepatitis B virus vaccination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/55/23416\">",
"           Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/59/35768\">",
"           Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/26/7591\">",
"           Overview of hepatitis A virus infection in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/45/43735\">",
"           Overview of the management of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/59/38841\">",
"           Patient selection for antiviral therapy for chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/55/41849\">",
"           Screening for and diagnosis of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/60/14281\">",
"           Standard and pegylated interferon for chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-9B955872D7-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f18_5_18514=[""].join("\n");
var outline_f18_5_18514=null;
var title_f18_5_18515="Esophageal cast tethered";
var content_f18_5_18515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophagitis dissecans superficialis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper endoscopy showing an esophageal cast still tethered to gastroesophageal junction in a patient wth esophagitis dissecans superficialis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of S. Ian Gan, MD, and Daniel Wild, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18515=[""].join("\n");
var outline_f18_5_18515=null;
var title_f18_5_18516="Domperidone: Patient drug information";
var content_f18_5_18516=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Domperidone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     see \"Domperidone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Domperidone&reg;;",
"     </li>",
"     <li>",
"      Dom-Domperidone;",
"     </li>",
"     <li>",
"      Mylan-Domperidone;",
"     </li>",
"     <li>",
"      Nu-Domperidone;",
"     </li>",
"     <li>",
"      PHL-Domperidone;",
"     </li>",
"     <li>",
"      PMS-Domperidone;",
"     </li>",
"     <li>",
"      RAN&trade;-Domperidone;",
"     </li>",
"     <li>",
"      ratio-Domperidone;",
"     </li>",
"     <li>",
"      Teva-Domperidone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691310",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used in patients getting tube feedings who have high residuals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2693940",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop upset stomach and throwing up caused by drugs for Parkinson's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692020",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat poor stomach clearing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to domperidone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: GI (gastrointestinal) bleeding, hole in the GI tract, or bowel block.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697190",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have breast cancer, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low potassium levels or if you are taking a water pill, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695822",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 15 to 30 minutes before meals and at bedtime.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11257 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18516=[""].join("\n");
var outline_f18_5_18516=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162491\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021177\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021179\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021178\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021183\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021184\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021186\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021181\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021182\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021187\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021188\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=related_link\">",
"      Domperidone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_5_18517="Rufinamide: Patient drug information";
var content_f18_5_18517=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rufinamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/30/5606?source=see_link\">",
"     see \"Rufinamide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/12/29893?source=see_link\">",
"     see \"Rufinamide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6802947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Banzel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13245578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Banzel&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692054",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rufinamide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703738",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Familial Short QT syndrome.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet can be crushed and mixed with food or liquid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3311839",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral suspension:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use carefully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696379",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Only use the measuring device that comes with this liquid drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3311839",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral suspension:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of suspension not used after 3 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store upright with the cap on.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12201 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-FB0AF5DF12-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18517=[""].join("\n");
var outline_f18_5_18517=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6802947\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13245578\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011665\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011667\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011666\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011671\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011672\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011674\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011669\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011670\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011675\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011676\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/30/5606?source=related_link\">",
"      Rufinamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/12/29893?source=related_link\">",
"      Rufinamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_5_18518="Moclobemide: Drug information";
var content_f18_5_18518=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Moclobemide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/10/13477?source=see_link\">",
"    see \"Moclobemide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F197419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Moclobemide&reg;;",
"     </li>",
"     <li>",
"      Dom-Moclobemide;",
"     </li>",
"     <li>",
"      Manerix&reg;;",
"     </li>",
"     <li>",
"      Novo-Moclobemide;",
"     </li>",
"     <li>",
"      Nu-Moclobemide;",
"     </li>",
"     <li>",
"      PMS-Moclobemide;",
"     </li>",
"     <li>",
"      Teva-Moclobemide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F197456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Monoamine Oxidase Inhibitor, Reversible",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F197422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Depressive illness:",
"     </b>",
"     Oral: Initial: 300 mg/day in 2 divided doses; may increase dose gradually beginning 1 week after therapy initiation. Maximum dose: 600 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Individual patient response may allow a reduction in daily dose in long-term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Coadministration with cimetidine:",
"     </i>",
"     A 50% reduction in the dose of moclobemide may be necessary",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11450084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; however, single-dose pharmacokinetic data suggests that dosage adjustments are not necessary (multiple-dose studies have not been performed). There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F197423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hepatic impairment: Decrease daily dose by 33% to 50%.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Apo-Moclobemide&reg;, Dom-Moclobemide, Manerix&reg; , Novo-Moclobemide, Nu-Moclobemide, PMS-Moclobemide: 100 mg, 150 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F197399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer immediately after meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F197398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of depressive illness",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F197454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (4%), hypotension (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Sleep disturbance (7%), agitation (5%), nervousness (4%), anxiety (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (4%), diarrhea (2%), vomiting (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Aggression, allergic reaction, angina, apathy, bradycardia, cold sensation, confusion, conjunctivitis, delusions, disorientation, dry skin, dysarthria, dyspnea, dysuria, excitation, extrapyramidal effects, extrasystoles, flushing, gastritis, gingivitis, hallucinations, heartburn, hypertension, indigestion, insomnia, irritability, malaise, mania, memory disturbances, meteorism, metrorrhagia, migraine, muscular pain, nightmares, paresthesia, phlebitic symptoms, photopsia, polyuria, prolonged menstruation, pruritus, rash, skeletal pain, stomatitis, taste alteration, tenesmus, tension, tinnitus, transaminases increased, urticaria, visual disturbances",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F197402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to moclobemide or any component of the formulation; acute confusional states; concurrent use of sympathomimetics (and related compounds), MAO inhibitors, meperidine, tricyclic antidepressants, thioridazine, serotonergic drugs (including SSRIs)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F197385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior: The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Use caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment due to decreased clearance; dose adjustment required in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma: Use with caution in patients with pheochromocytoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyrotoxicosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anesthesia: Discontinue at least 2 days prior to local or general anesthesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Buspirone: Use with caution in patients receiving concurrent buspirone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonergic agents: Severe reactions may occur when used concurrently with MAO inhibitors and serotonergic agents, including SSRIs. Do not use within 5 weeks of fluoxetine discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tricyclic antidepressants: Do not initiate therapy until moclobemide has been discontinued for &ge;2 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Slow metabolizers: Serum concentrations may be increased in patients who are slow CYP2D6 and/or CYP2C19 metabolizers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tyramine restriction: Dietary restriction of tyramine does not appear to be necessary for patients receiving moclobemide (patients must be informed of signs/symptoms of reaction).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F197451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C19 (moderate), CYP2D6 (weak), Monoamine Oxidase",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F197389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): MAO Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Indirect-Acting): MAO Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: MAO Inhibitors may enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists (Ophthalmic): MAO Inhibitors may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of MAO Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: MAO Inhibitors may enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome. Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): MAO Inhibitors may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: MAO Inhibitors may enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: MAO Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: MAO Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: MAO Inhibitors may enhance the neurotoxic (central) effect of BuPROPion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the adverse/toxic effect of MAO Inhibitors. Specifically, blood pressure elevations been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of MAO Inhibitors. Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Moclobemide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclobenzaprine: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: MAO Inhibitors may enhance the hypertensive effect of Dexmethylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: MAO Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diethylpropion: MAO Inhibitors may enhance the hypertensive effect of Diethylpropion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxapram: MAO Inhibitors may enhance the hypertensive effect of Doxapram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HYDROmorphone: MAO Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: MAO Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: May enhance the adverse/toxic effect of MAO Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: MAO Inhibitors may enhance the adverse/toxic effect of Linezolid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maprotiline: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: MAO Inhibitors may enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: MAO Inhibitors may enhance the adverse/toxic effect of Methadone.  Management: Initial safety testing, where small incremental doses of methadone are given with the patient closely monitored (including vitals, etc.), is recommended if methadone is to be used with (or within 14 days of) an MAO inhibitor. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: MAO Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: MAO Inhibitors may enhance the hypertensive effect of Methylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: MAO Inhibitors may enhance the neurotoxic (central) effect of Mirtazapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orthostatic Hypotension Producing Agents: MAO Inhibitors may enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxymorphone: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pizotifen: MAO Inhibitors may enhance the anticholinergic effect of Pizotifen.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: MAO Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: MAO Inhibitors may decrease the metabolism of Serotonin 5-HT1D Receptor Agonists.  Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Eletriptan; Frovatriptan; Naratriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrahydrozoline (Nasal): MAO Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: Moclobemide may increase the serum concentration of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors. Management: Consider alternatives to combined treatment with tramadol and monoamine oxidase inhibitors due to an increased risk of serotonin syndrome and seizures. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: MAO Inhibitors may enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F197416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Dietary restriction of tyramine does not appear to be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, SAMe, ginseng. Avoid ginkgo (may lead to MAO inhibitor toxicity). Avoid ephedra, yohimbe (can cause hypertension). Avoid kava (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F197405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety has not been established, use only if benefits outweigh the risks.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F197425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F197406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Less than 1% of maternal dose is excreted in breast milk; benefits should outweigh risks.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F197407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken immediately after meals. Manufacturer states no special dietary restrictions are required; tyramine-containing foods may be ingested during therapy. However, as a precaution, patients should be instructed to recognize occipital headache, palpitations, neck stiffness, or other potential signs of a severe reaction.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F197394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, warning signs of suicide",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F197408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Akenex (AR);",
"     </li>",
"     <li>",
"      Amira (AU);",
"     </li>",
"     <li>",
"      Animex (UY);",
"     </li>",
"     <li>",
"      Aurorex (EC, MX, PE);",
"     </li>",
"     <li>",
"      Aurorix (AR, AT, AU, BE, BG, BR, CH, CN, CZ, DK, EE, FI, GR, HK, HN, HR, HU, ID, IT, KP, LU, NL, NO, PH, PK, PL, PT, SE, TH, TR, UY);",
"     </li>",
"     <li>",
"      Biorix (TW);",
"     </li>",
"     <li>",
"      Clorix (ZA);",
"     </li>",
"     <li>",
"      Feraken (MX);",
"     </li>",
"     <li>",
"      Inpront (CN);",
"     </li>",
"     <li>",
"      Langtian (CL);",
"     </li>",
"     <li>",
"      Manerix (ES, GB, IE);",
"     </li>",
"     <li>",
"      Mobemide (IL, SG);",
"     </li>",
"     <li>",
"      Moclamine (FR);",
"     </li>",
"     <li>",
"      Moclod (TW);",
"     </li>",
"     <li>",
"      Moclodura (DE);",
"     </li>",
"     <li>",
"      Morex (IN);",
"     </li>",
"     <li>",
"      Rimarex (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F197384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moclobemide is a benzamide derivative which acts as a short-acting reversible inhibitor of monoamine oxidase (MAO), which inhibits the metabolism (deamination) of serotonin, norepinephrine, and dopamine. It has a relative specificity for the A subtype of monoamine oxidase (MAO type A). Its action leads to increased concentrations of these neurotransmitters, which may account for the antidepressant activity of moclobemide.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F197401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 98% from GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 1.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~50% (primarily to albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively metabolized via hepatic oxidative reactions; partial metabolism via CYP2C19 and 2D6",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~55% (single dose); 90% (repeated dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (95%, as metabolites; &lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10059 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-EBA391572F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18518=[""].join("\n");
var outline_f18_5_18518=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197419\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197456\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197422\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062618\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11450084\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197423\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076312\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234098\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197399\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197398\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197454\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197402\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197385\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197451\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197389\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197416\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197405\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197425\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197406\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197407\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197394\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197408\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197384\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197401\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10059\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10059|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/10/13477?source=related_link\">",
"      Moclobemide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_5_18519="Atrophic rhinosinusitis";
var content_f18_5_18519=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atrophic rhinosinusitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/5/18519/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/5/18519/contributors\">",
"     Richard D deShazo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/5/18519/contributors\">",
"     Scott Stringer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/5/18519/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/5/18519/contributors\">",
"     Jonathan Corren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/5/18519/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/5/18519/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/5/18519/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrophic rhinitis is an uncommon and distinct clinical syndrome of progressive atrophy of the nasal mucosa with paradoxical nasal congestion, complicated by bacterial colonization and infection and thick, troublesome nasal secretions. Enlargement of the nasal cavities may occur in some forms. Most patients also have concomitant sinusitis and thus the disorder is more accurately called atrophic rhinosinusitis. There are primary and secondary forms of this disorder, which affect different populations and have distinct presentations.",
"   </p>",
"   <p>",
"    This topic will discuss the classification, clinical manifestations, diagnosis, and management of atrophic rhinosinusitis. Other forms of chronic rhinosinusitis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18731467\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrophic rhinosinusitis may be categorized into two forms: primary (or idiopathic) and secondary.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary form is seen primarily in young people in the developing world. It is associated with mucosal colonization predominantly with Klebsiella ozaenae as well as other organisms. The primary presenting symptom is foul smelling nasal discharge.",
"     </li>",
"     <li>",
"      Secondary atrophic rhinosinusitis is seen with some regularity in the developed world and occurs in patients who underwent prior sinonasal trauma, surgery, radiation therapy, or have certain inflammatory conditions (granulomatous diseases).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRIMARY ATROPHIC RHINOSINUSITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary (idiopathic) atrophic rhinosinusitis is principally reported among patients from lower socioeconomic groups living in geographic areas with warm climates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Areas of high prevalence include southern Saudi Arabia, China, Africa, India, the Mediterranean, and the Philippines. It is uncommon in the United States and Europe, although it should be considered in immigrants from these areas [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/4\">",
"     4",
"    </a>",
"    ]. The low incidence in developed countries has been suggested to be at least in part due to widespread availability of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/5\">",
"     5",
"    </a>",
"    ]. By definition, there is no history of nasal trauma or surgery, granulomatous disease, or sinonasal radiation prior to the onset of symptoms.",
"   </p>",
"   <p>",
"    Women are affected more often than men, and younger people more often than older adults. [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. In one study of 100 cases from China, 86 patients were less than 30 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with primary atrophic rhinosinusitis present with halitosis that is noticeable to others and the constant perception of a bad odor (cacosmia). This is the origin of the term \"ozena\" (\"the stench&rdquo;), which is sometimes used as a synonym for severe primary atrophic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/3\">",
"     3",
"    </a>",
"    ]. However, this unfortunate descriptor both stigmatizes and embarrasses affected patients and should be avoided. Other symptoms include anosmia, epistaxis, nasal pain, sleep disruption, and choking from aspiration of crusts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/5,7,8\">",
"     5,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a Thai series of 47 patients with primary atrophic rhinosinusitis, the most common presenting symptoms were nasal crusts (54 percent), purulent discharge (43 percent), foul smell (41 percent), and nasal obstruction (37 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may report congestion even with abnormally enlarged nasal cavities, because the sensation of obstruction can arise from abnormal airflow through the nose. The same phenomenon is seen in patients with nasal septal perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nasal exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal exam reveals a shiny, thin, pale, and sometimes ulcerated mucosa covered by thick yellow, brown, or green crusts, which may be bloody or covered with purulence. Resorption of underlying bone leads to enlargement of the nasal cavities and bowing of the lateral nasal wall in some cases. Saddle nose deformity and nasal septal perforation may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3730026\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors that predispose certain individuals to develop primary atrophic rhinitis are not definitively known, although various developmental, endocrine, vascular, nutritional, anatomic, infectious, and autoimmune factors have been postulated to be relevant. In the Thai study, many patients either came from rural areas or worked in factories, suggesting that specific environmental exposures may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/3\">",
"     3",
"    </a>",
"    ]. A genetic association was suggested in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologically, the disease is characterized by replacement of the normal pseudostratified columnar epithelium with a metaplastic, predominantly squamous epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. This abnormal tissue is devoid of cilia and mucus-producing goblet cells. Additional findings may include an inflammatory cell infiltrate composed of lymphocytes and plasma cells, and vascular abnormalities ranging from neovascularity to arteritis obliterans (",
"    <a class=\"graphic graphic_table graphicRef50119 \" href=\"UTD.htm?2/11/2235\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonization and frank infection of the nose and sinuses occurs with Klebsiella ozaenae and other organisms, including Proteus species, Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, and others [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/3,12\">",
"     3,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) may reveal some combination of the following features (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64095 \" href=\"UTD.htm?7/41/7825\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mucosal atrophy of the inferior and middle meatus and bony resorption",
"     </li>",
"     <li>",
"      Resorption of the ethmoid bulla and uncinate process with loss of definition of the osteomeatal complex",
"     </li>",
"     <li>",
"      Enlargement of the nasal cavities with destruction of the lateral nasal wall",
"     </li>",
"     <li>",
"      Mucosal thickening in the paranasal sinuses",
"     </li>",
"     <li>",
"      Hypoplasia of the maxillary sinuses with decreased pneumatization",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SECONDARY ATROPHIC RHINOSINUSITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on patients with secondary atrophic rhinosinusitis are sparse, although such patients are not unusual in referral practices in allergy-immunology and otolaryngology. A common feature is long-standing nasal trauma or inflammation, culminating in mucosal damage, nasal crusting, and superinfection. Patients with atrophic rhinitis differ from those with standard chronic rhinosinusitis in the intractable nature of their symptoms and ongoing mucopurulence.",
"   </p>",
"   <p>",
"    We distinguish two subtypes of secondary atrophic rhinitis &ndash; a &ldquo;wet&rdquo; form and a &ldquo;dry&rdquo; form.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The typical patient with the wet form is one who has had multiple sinus surgeries and now experiences chronic rhinosinusitis with production of purulent mucous. When cultured, the nasal discharge grows coliforms, often E. coli. Most patients we see have been treated with multiple antibiotics to the point that these organisms are resistant to all antibiotics. These patients have stagnant mucus that is superinfected, rather than a traditional sinusitis. Antibiotics do not resolve this condition and often make it worse.",
"     </li>",
"     <li>",
"      Patients with the &ldquo;dry form&rdquo; of secondary atrophic rhinitis have dry noses with bloody scabs. We see this most commonly with sarcoidosis of the upper respiratory tract.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary atrophic rhinosinusitis is seen in association with [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repeated sinonasal surgeries: Surgery can both cause and exacerbate atrophic rhinosinusitis. Affected patients may have undergone multiple sinus surgeries (often with radical middle turbinectomy) for chronic rhinosinusitis, allergic fungal sinusitis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nasal sarcoidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/14\">",
"       14",
"      </a>",
"      ]. This form of iatrogenic secondary atrophic rhinitis is sometimes called &ldquo;empty nose syndrome&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sinonasal trauma, especially trauma requiring extensive surgical corrections.",
"     </li>",
"     <li>",
"      Sinonasal radiation.",
"     </li>",
"     <li>",
"      Granulomatous diseases of the upper respiratory tract, such as leprosy, tuberculosis, sarcoidosis, granulomatosis with polyangiitis (Wegener&rsquo;s), or syphilis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a review of 242 patients, of whom 197 had secondary atrophic rhinosinusitis, all reported congestion, daily nasal crusting, and dryness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/5\">",
"     5",
"    </a>",
"    ]. About one-half of patients experienced social isolation and depression. Other common symptoms were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Facial pain",
"     </li>",
"     <li>",
"      Recurrent epistaxis",
"     </li>",
"     <li>",
"      Episodic anosmia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with secondary atrophic rhinitis may also report persistent post-nasal drip, cacosmia, and episodes of frank sinusitis. Some present as \"nasal cripples,\" or people whose lives are disrupted by persistent nasal symptoms.",
"   </p>",
"   <p>",
"    Some patients have thick, viscous, mucopurulent secretions, and these individuals may have underlying inflammatory diseases. In contrast, others report intractable nasal dryness and may use tweezers to remove dry, bloody crusts from the nasal passages [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/16\">",
"     16",
"    </a>",
"    ]. This \"dry\" presentation may represent a later stage of the disease that results from destruction and loss of the mucus secreting glandular epithelium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nasal exam findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhinoscopy usually reveals a thin edematous or granular, erythematous mucosa, with lesser degrees of nasal bleeding, crusting, and purulence. Widening of the nasal airway due to resorption of underlying cartilage is less common with the secondary forms of the disease, compared with primary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the authors&rsquo; experience, superinfection on nasal culture is more common with Pseudomonas aeruginosa and Staphylococcus aureus than with other organisms. It is frequently difficult to assess if symptoms are related to bacterial infection or if the bacteria represent colonization of a damaged epithelium with poor mucociliary function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single set of radiologic findings pathognomonic for secondary atrophic rhinosinusitis. Radiographic findings reflect secondary infection complicating the atrophic rhinosinusitis, rather than the atrophic changes directly [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/16\">",
"     16",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Post-surgical atrophic rhinosinusitis may appear on CT as an absence or reduction in the size of the middle or inferior turbinates, nearly complete absence of the septae of the ethmoid sinuses,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mucosal thickening throughout the paranasal sinuses.",
"     </li>",
"     <li>",
"      Granulomatous and post-radiation-induced atrophic rhinosinusitis may be manifest radiologically by diffuse mucosal changes throughout the paranasal sinuses and a marked prominence of the soft tissues of the turbinates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic findings in secondary atrophic rhinosinusitis are similar to those of primary disease; however, vascular changes and resorption of bone are not observed (",
"    <a class=\"graphic graphic_table graphicRef50119 \" href=\"UTD.htm?2/11/2235\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis (either primary or secondary) is based upon the presence of appropriate symptoms and physical findings, combined with consistent findings on computerized tomography (CT) of the sinuses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H560366\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic criteria for",
"    <strong>",
"     secondary",
"    </strong>",
"    atrophic rhinosinusitis have been proposed, which incorporate elements of the history and physical examination. These criteria were based on an analysis of 22 patients, in whom there was consensus between the treating otolaryngologist and",
"    <span class=\"nowrap\">",
"     allergist/immunologist",
"    </span>",
"    that the best diagnosis was atrophic rhinosinusitis, compared to 22 patients with various other types of chronic rhinosinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Six criteria were identified that were characteristic and specific to patients with secondary atrophic rhinitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient reported:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Recurrent epistaxis",
"     </li>",
"     <li>",
"      Episodic anosmia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinician documented:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nasal purulence",
"     </li>",
"     <li>",
"      Nasal crusting",
"     </li>",
"     <li>",
"      Chronic inflammatory disease involving the upper airway (eg, sarcoidosis, granulomatosis with polyangiitis, etc)",
"     </li>",
"     <li>",
"      Two or more sinus surgeries",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with",
"    <strong>",
"     two or more criteria",
"    </strong>",
"    could be assigned the diagnosis of atrophic rhinitis with a sensitivity of 0.95 and a specificity of 0.77 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Of note, chronic nasal obstruction was common but not specific to patients with atrophic rhinosinusitis, so this was excluded as a criterion. The six criteria listed above occurred more often in patients with atrophic rhinitis compared to other forms of rhinosinusitis.",
"   </p>",
"   <p>",
"    In addition to the standard history and physical examination, we perform rhinoscopy with a nasal endoscope after spraying the nose with a topical",
"    <span class=\"nowrap\">",
"     anesthetic/decongestant.",
"    </span>",
"    Although the findings may be detectable with a simple nasal speculum exam in some cases, rhinoscopy allows for a more complete appreciation of the extent of disease and is essential in subsequent management. Rhinoscopy is usually performed by an otolaryngologist or by an allergist with specific training in this procedure.",
"   </p>",
"   <p>",
"    Nasal cultures positive for coliforms are supportive of the diagnosis, although these are not routinely performed or used to guide therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H560424\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT is the recommended imaging methodology for evaluation of patients with symptoms consistent with atrophic rhinosinusitis (if not already performed). Routine sinus radiographs are no longer used in the evaluation of rhinosinusitis in developed countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Evaluation for underlying systemic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An undetected inflammatory disorder, such as leprosy, sarcoidosis, granulomatosis with polyangiitis (Wegener&rsquo;s), or syphilis, should be considered if systemic symptoms such as weight loss or shortness of breath are present or if there is chronic epistaxis. In this setting, laboratory evidence of a systemic disorder, such as hematologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal abnormalities, or an abnormal chest radiograph, may also suggest an underlying inflammatory process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Nasal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nasal biopsy should be obtained if there is a question of secondary atrophic rhinosinusitis due to an underlying inflammatory process. Depending on the patient's history, examination for fungus, acid fast mycobacteria, spirochetes, or granulomatous changes may be helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=see_link\">",
"     \"Fungal rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;Rhinitis sicca anterior&rdquo; and dry nose syndromes are poorly defined disorders that probably sit on the continuum from mild to severe secondary atrophic rhinitis.",
"   </p>",
"   <p>",
"    Additional discussions related to the differential diagnosis of patients with symptoms and signs suggestive of rhinosinusitis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=see_link\">",
"     \"Chronic nonallergic rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link\">",
"     \"An overview of rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled trials evaluating therapies for atrophic rhinosinusitis are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/18\">",
"     18",
"    </a>",
"    ], and the literature supporting various therapies is limited to observational studies and case reports. Our approach to management of atrophic rhinosinusitis is empiric, and is described in detail in the following section. Daily therapy includes nasal lavage and lubrication. Topical antibiotics are added when indicated, as specified below. Any underlying active disease process, such as sarcoidosis or granulomatosis with polyangiitis (Wegener's), must be treated if present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nasal lavage and lubrication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal lavage is recommended to prevent formation of crusts and drying of the atrophic nasal lining. It is associated with improvement in a variety of rhinitis conditions and carries little risk if properly performed, although it has not been specifically studied in the treatment of atrophic rhinosinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with atrophic rhinosinusitis are encouraged to lavage their noses with warmed isotonic saline at least twice daily (",
"    <a class=\"graphic graphic_table graphicRef78832 \" href=\"UTD.htm?21/16/21772\">",
"     table 2",
"    </a>",
"    ). We recommend using a Water Pik device with a Grossan tip (Hydro Med, Kenwood Therapeutics). Other devices, such as bulb syringes, bottle sprayers, and nebulizers are also effective, provided the system delivers an adequate volume of solution (&gt;200 mL per side) into the nose [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After lavage, we use one of several agents to lubricate the mucosa. Acceptable products include petroleum jelly or personal lubricants such as KY Liquid (McNeil PPC, Inc.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data exist concerning the efficacy of antibiotics added to lavage solutions in atrophic rhinosinusitis. However, case reports and small series of patients with recalcitrant rhinitis from various etiologies have found the intervention helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/20\">",
"     20",
"    </a>",
"    ]. Theoretically, lavage with antibiotic solutions provides relatively high concentrations of drug directly to the nasal cavity, which is the site of the pathology in atrophic rhinosinusitis, in contrast to chronic sinusitis, in which the pathology involves the sinuses more than the nasal passages.",
"   </p>",
"   <p>",
"    It has been our experience that this intervention is helpful. An antibiotic may be added to the lavage when the nasal wash or nasal discharge becomes persistently purulent for more than two days (",
"    <a class=\"graphic graphic_table graphicRef55661 \" href=\"UTD.htm?9/54/10091\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/20\">",
"     20",
"    </a>",
"    ]. We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    initially. The antibiotic solution is used twice daily until the patient no longer notes purulent nasal discharge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    purulence clears from the lavage solution.",
"   </p>",
"   <p>",
"    The oral administration of antibiotics may also be required for acute infections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/21\">",
"     21",
"    </a>",
"    ]. We generally use quinolones or other broad spectrum antibiotics for patients with secondary disease, although there are no specific studies examining choice of antibiotics in this situation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    has been studied in a small number of patients with the primary form of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20790803\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with secondary atrophic rhinitis and active nasal inflammation, we use intranasal glucocorticoids either in nasal sprays or lavage. We have not observed any complications and often there is some symptomatic improvement in our experience. However, other experts suggest avoiding intranasal glucocorticoids, and data are lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10110674\">",
"    <span class=\"h2\">",
"     Therapies that are not recommended",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decongestants, both oral and topical, may be harmful to the already compromised vascular supply to the nasal mucosal tissues. We advise patients to avoid these.",
"   </p>",
"   <p>",
"    A number of surgical procedures have been proposed; however, controlled trials have not been performed to adequately assess their efficacy. These include temporary closure of the nostrils to facilitate regrowth of the nasal epithelium (Young's Operation), surgical implantation of acrylic, Teflon, silastic, or polyethylene materials to form a lattice for tissue regrowth, flap procedures, injection of allogeneic bone or fat, and injection of placental tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18519/abstract/1,22\">",
"     1,22",
"    </a>",
"    ]. Since adequate scientific scrutiny has not been performed, these procedures are",
"    <strong>",
"     not",
"    </strong>",
"    recommended at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20790815\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform surveillance rhinoscopy (with a nasal endoscope at least twice a year) as long as symptoms persist to remove adhesions (synechiae) and excessive crusting. This should be performed by an otolaryngologist or other clinician trained in endoscopic rhinoscopy, as excessive bleeding may result if the procedure is improperly done.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3730256\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many cases, atrophic rhinosinusitis is a lifelong condition. However, in our experience, the secondary form of the disease seems to \"burn out\" spontaneously in a subset of patients; that is, the wet form sometimes transforms into the dry form. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Secondary atrophic rhinosinusitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/18/16674?source=see_link\">",
"       \"Patient information: Rinsing out your nose with salt water (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrophic rhinosinusitis is a syndrome of progressive atrophy and bacterial colonization of the nasal mucosa. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Primary (idiopathic) atrophic rhinosinusitis is the more severe form of the condition and is predominantly seen in developing countries. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Primary atrophic rhinosinusitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The secondary form, which is associated with nasal surgery, trauma, radiation, and granulomatous diseases, is more common in developed countries. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Secondary atrophic rhinosinusitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms include chronic nasal congestion, crusting of nasal secretions, halitosis, anosmia, epistaxis, sleep disruption, and depression. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Symptoms and signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rhinoscopy reveals a thin, erythematous mucosa, with nasal bleeding, crusting, and purulence. The nasal cavities may become enlarged, particularly in the primary form. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nasal exam'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Nasal exam findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of atrophic rhinosinusitis (either primary or secondary) is based upon the combination of suggestive symptoms, rhinoscopy findings, and radiographic results. Diagnostic criteria have been proposed. The possibility of an underlying and causative disease should be investigated in patients with apparent systemic illness. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no controlled trials comparing therapies for atrophic rhinitis. If secondary atrophic rhinosinusitis is due to an underlying active disease process, then therapy should focus on the underlying disease. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest nasal lavage with warmed normal saline at least twice daily (",
"      <a class=\"graphic graphic_table graphicRef78832 \" href=\"UTD.htm?21/16/21772\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). After lavage, we suggest that patients lubricate the cleaned nasal mucosa with petroleum jelly or personal lubricants (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Nasal lavage and lubrication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that an antibiotic be added to the lavage solution when the nasal wash or nasal discharge becomes purulent for more than two days (",
"      <a class=\"graphic graphic_table graphicRef55661 \" href=\"UTD.htm?9/54/10091\">",
"       table 3",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This is continued until the purulence clears. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral antibiotics are used for acute bacterial sinus infections. We suggest quinolones for initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest performing rhinoscopy at least twice yearly to remove synechiae and crusts as long as symptoms persist (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20790815\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest AGAINST the various surgical interventions that appear in the literature (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10110674\">",
"       'Therapies that are not recommended'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/1\">",
"      Dutt SN, Kameswaran M. The aetiology and management of atrophic rhinitis. J Laryngol Otol 2005; 119:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/2\">",
"      Zohar Y, Talmi YP, Strauss M, et al. Ozena revisited. J Otolaryngol 1990; 19:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/3\">",
"      Bunnag C, Jareoncharsri P, Tansuriyawong P, et al. Characteristics of atrophic rhinitis in Thai patients at the Siriraj Hospital. Rhinology 1999; 37:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/4\">",
"      Lee YJ, Moore LS, Almeyda J. A report on a rare case of Klebsiella ozaenae causing atrophic rhinitis in the UK. BMJ Case Rep 2011; 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/5\">",
"      Moore EJ, Kern EB. Atrophic rhinitis: a review of 242 cases. Am J Rhinol 2001; 15:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/6\">",
"      Han-Sen C. The ozena problem. Clinical analysis of atrophic rhinitis in 100 cases. Acta Otolaryngol 1982; 93:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/7\">",
"      Chand MS, MacArthur CJ. Primary atrophic rhinitis: a summary of four cases and review of the literature. Otolaryngol Head Neck Surg 1997; 116:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/8\">",
"      El-Barbary A, Yassin A, Fouad H, Shennany M. Histopathological and histochemical study on atrophic rhinitis. J Laryngol Otolaryngol 1970; 84:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/9\">",
"      Kameswaran M. Fibre-optic endoscopy in atrophic rhinitis. J Laryngol Otol 1991; 105:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/10\">",
"      Sibert JR, Barton RP. Dominant inheritance in a family with primary atrophic rhinitis. J Med Genet 1980; 17:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/11\">",
"      Abdel-Latif SM, Baheeg SS, Aglan YI, et al. Chronic atrophic rhinitis with fetor (ozena): a histopathologic tretise. Rhinology 1987; 25:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/12\">",
"      Ferguson JL, McCaffrey TV, Kern EB, Martin WJ 2nd. Effect of Klebsiella ozaenae on ciliary activity in vitro: implications in the pathogenesis of atrophic rhinitis. Otolaryngol Head Neck Surg 1990; 102:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/13\">",
"      Pace-Balzan A, Shankar L, Hawke M. Computed tomographic findings in atrophic rhinitis. J Otolaryngol 1991; 20:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/14\">",
"      Castillo L, Verschuur HP, Poissonnet G, et al. Complications of endoscopically guided sinus surgery. Rhinology 1996; 34:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/15\">",
"      Hildenbrand T, Weber RK, Brehmer D. Rhinitis sicca, dry nose and atrophic rhinitis: a review of the literature. Eur Arch Otorhinolaryngol 2011; 268:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/16\">",
"      Ly TH, deShazo RD, Olivier J, et al. Diagnostic criteria for atrophic rhinosinusitis. Am J Med 2009; 122:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/17\">",
"      deShazo RD, Stringer SP. Atrophic rhinosinusitis: progress toward explanation of an unsolved medical mystery. Curr Opin Allergy Clin Immunol 2011; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/18\">",
"      Mishra A, Kawatra R, Gola M. Interventions for atrophic rhinitis. Cochrane Database Syst Rev 2012; 2:CD008280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/19\">",
"      Tomooka LT, Murphy C, Davidson TM. Clinical study and literature review of nasal irrigation. Laryngoscope 2000; 110:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/20\">",
"      Leonard DW, Bolger WE. Topical antibiotic therapy for recalcitrant sinusitis. Laryngoscope 1999; 109:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/21\">",
"      Sinha SN, Sardana DS, Rajvanshi VS. A nine years' review of 273 cases of atrophic rhinitis and its management. J Laryngol Otol 1977; 91:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18519/abstract/22\">",
"      Jaswal A, Jana AK, Sikder B, et al. Novel treatment of atrophic rhinitis: early results. Eur Arch Otorhinolaryngol 2008; 265:1211.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7531 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18519=[""].join("\n");
var outline_f18_5_18519=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18731467\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRIMARY ATROPHIC RHINOSINUSITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nasal exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3730026\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Microbiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SECONDARY ATROPHIC RHINOSINUSITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nasal exam findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Microbiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H560366\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H560424\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Evaluation for underlying systemic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Nasal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nasal lavage and lubrication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20790803\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10110674\">",
"      Therapies that are not recommended",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20790815\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3730256\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/7531\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/7531|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/41/7825\" title=\"diagnostic image 1\">",
"      Atroph rhin exp nasal cavity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/7531|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2235\" title=\"table 1\">",
"      Histopathology atropic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/16/21772\" title=\"table 2\">",
"      Nasal irrigation for atrophic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/54/10091\" title=\"table 3\">",
"      Management atrophic rhinitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=related_link\">",
"      An overview of rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=related_link\">",
"      Chronic nonallergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=related_link\">",
"      Fungal rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/18/16674?source=related_link\">",
"      Patient information: Rinsing out your nose with salt water (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_5_18520="Structures of the axilla";
var content_f18_5_18520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Structures of the axilla",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 471px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Structures of the axilla. Most of the anterior wall of the axilla and the axillary fat pad have been removed, revealing the axilla's medial and posterior walls and neurovascular contents. Of the structures forming the anterior wall, only portions of the pectoralis major (attaching ends, a central part overlying the pectoralis minor, and a cube of muscle reflected superior to the clavicle) and the pectoralis minor remain. All the clavipectoral fascia has been removed, as has the axillary sheath surrounding the neurovascular bundle. Observe the axillary artery emerging from the cervicoaxillary canal inferior to the clavicle and subclavius muscle and then passing a finger's breadth inferior to the coracoid process of the scapula. As the axillary artery passes through the axilla, it is surrounded by the brachial plexus of nerves. The major nerves arising from the lateral and medial cords (anterior divisions) of the plexus have been elevated by an applicator stick.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AF. Clinical Oriented Anatomy, Fourth Ed. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18520=[""].join("\n");
var outline_f18_5_18520=null;
var title_f18_5_18521="Assessing the probability of developing rheumatoid arthritis in patients with undifferentiated inflammatory arthritis";
var content_f18_5_18521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessing the probability of developing rheumatoid arthritis in patients with undifferentiated inflammatory arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/5/18521/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/5/18521/contributors\">",
"     Josef S Smolen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/5/18521/contributors\">",
"     Daniel Aletaha, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/5/18521/contributors\">",
"     Klaus P Machold, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/5/18521/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/5/18521/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/5/18521/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/5/18521/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/5/18521/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint destruction, disability, and premature mortality are the major adverse outcomes of rheumatoid arthritis (RA) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Slowing and even the prevention of structural damage over the short term are now possible in most patients through effective therapy. This consists of synthetic disease modifying antirheumatic drugs (DMARDs), glucocorticoids, and biological agents. Additional relief is provided by physical therapy, nonsteroidal antiinflammatory drugs, and, with decreasing frequency over the last decade, surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erosions, periarticular osteopenia, and cartilage loss may already be seen when patients present for the first time within a few weeks from the onset of symptoms but almost invariably occur within the first two years of RA onset in the absence of effective treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. The extent of irreversible joint damage and disability will primarily depend upon the time that elapses before a satisfactory treatment effect is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, effective strategies designed to disrupt the pathophysiology of RA and prevent the long-term effects of this disease depend largely upon the initiation of treatment early in the disease course [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term &ldquo;early RA&rdquo; is not defined precisely in the literature and has become a moving target as more tests for early diagnosis become available. For the practical purposes of this discussion, an early diagnosis of RA is considered to be within three to six months of the onset of joint symptoms.",
"   </p>",
"   <p>",
"    Issues related to making the diagnosis of early RA, before the development of features typical of more established disease, are presented here. The general approach to the diagnosis of RA and the clinical features and treatment of this disorder are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION CRITERIA FOR RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA patients demonstrate considerable variability in both their presenting symptoms and initial laboratory results [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Classification criteria, developed to facilitate clinical research rather than to serve as a basis for clinical diagnosis, aim to maximize diagnostic specificity and foster uniformity among patients included in clinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for better tools for the identification of patients with early RA, from among individuals presenting with any type of inflammatory synovitis, led to the development in 2010 of the American College of Rheumatology",
"    <span class=\"nowrap\">",
"     (ACR)/European",
"    </span>",
"    League Against Rheumatism (EULAR) classification criteria for RA, which have greater sensitivity for the diagnosis of RA in early disease than the widely used 1987 ACR revised criteria for the classification of RA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The 2010 criteria also incorporate testing for anti-citrullinated peptide antibodies (ACPA) and measurement of acute phase reactants, both of which were not included in the older criteria. Additionally, individual criteria can be counted cumulatively over time, rather than having to coexist at a single time point. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\", section on 'Classification criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2010",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    criteria are shown in detail at:",
"    <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/classification/ra/ra_2010.asp\">",
"     www.rheumatology.org/practice/clinical/classification/ra/ra_2010.asp",
"    </a>",
"    (accessed September 21, 2010).",
"   </p>",
"   <p>",
"    The major disadvantage of the 1987 ACR criteria (",
"    <a class=\"graphic graphic_table graphicRef71659 \" href=\"UTD.htm?4/13/4316\">",
"     table 1",
"    </a>",
"    ) was that they were developed to differentiate established RA from other established rheumatic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/13\">",
"     13",
"    </a>",
"    ]. Neither the 1987 nor the 2010 sets of classification criteria were designed to serve as diagnostic criteria. However, clinicians have used the classification criteria in the past to assist in diagnosis and are likely to continue to do so, although the criteria are best suited for use in clinical research. Further studies are needed to determine how to best incorporate them, if at all, into routine clinical care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF EARLY RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clues to the presence of early RA can be found in the history, physical examination, laboratory tests, and imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmarks of early RA in the patient's history include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Polyarticular involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Established RA tends to involve multiple joints over a period of months or years. As an example, one trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for the treatment of established RA reported mean baseline swollen and tender joint counts of 12 and 30, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/16\">",
"     16",
"    </a>",
"    ]. However, at the time of first presentation, many patients eventually diagnosed with RA may have only a small number of joints affected. In a review of 1700 patients followed in an &ldquo;early arthritis&rdquo; clinic, the patients subsequently diagnosed as having RA had a median of four swollen joints and eight tender joints at the time of enrollment into the cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/17\">",
"     17",
"    </a>",
"    ]. These figures are approximately twice the number of swollen and tender joints detected among patients who did not evolve clear-cut diagnoses of RA over time.",
"   </p>",
"   <p>",
"    The 1987 ACR classification criteria often led to a biased focus on patients with polyarthritis among those with early arthritis. In contrast to the arthritis of rheumatoid factor-positive patients, the peripheral arthritis of most &ldquo;seronegative&rdquo; spondyloarthropathies, such as reactive arthritis, arthritis of inflammatory bowel disease, or ankylosing spondylitis, is usually oligoarticular or monoarticular. Nevertheless, as mentioned above, RA may start with involvement of only few joints, and the 2010",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    classification criteria account for this fact by different weighting for high versus low joint counts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Morning stiffness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morning stiffness is a typical symptom of inflammatory disease involving the finger joints. Stiffness after awakening that lasts at least 60 minutes constitutes one of the seven 1987 ACR criteria for classification of established RA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/13\">",
"     13",
"    </a>",
"    ]. By comparison, osteoarthritis patients typically have morning stiffness that does not exceed 30 minutes in duration. Referral to a rheumatologist is justified for patients who present with stiffness in the joints that persists for longer than 30 minutes after awakening [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Chronicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA is a chronic disease. In contrast, a variety of conditions can lead to transient joint inflammation that resolves of its own accord within days to weeks. Forms of arthritis induced by viral infections (eg, parvovirus B19) are particularly prominent among such conditions. Definite classification as having RA using the 1987 criteria required that patients have arthritis for at least six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/13,19,20\">",
"     13,19,20",
"    </a>",
"    ]; the new criteria allow for classification as RA in some patients with arthritis present less than six weeks, if a number of other criteria are met. Thus, earlier institution of disease modifying antirheumatic drugs may occur more readily, given the importance of preventing joint damage, if these criteria are used by clinicians to support early diagnosis of RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=see_link\">",
"     \"Specific viruses that cause arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination may also reveal features suggestive of early RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Joint tenderness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovitis of the metacarpophalangeal (MCP) and metatarsophalangeal (MTP) joints is often recognized by the finding of pain with compression. In a report of 524 consecutive patients with early arthritis, a positive compression test of the bilateral MTP joints in patients with early arthritis was a strong predictor of progression to erosive RA, second only to seropositivity for ACPA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Rheumatoid nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid nodules are one of the seven ACR criteria for established RA. However, rheumatoid nodules are often absent within the first few months to years of the onset of synovitis. Thus, their absence at presentation is not evidence against the diagnosis of RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=see_link\">",
"     \"Rheumatoid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Symmetric arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic RA involves the joints in a symmetric manner [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/17\">",
"     17",
"    </a>",
"    ]. However, in early disease, symmetry is often not apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Asymmetric and even monoarticular presentations are often observed. Patients with monoarthritis of a large joint, however, will not meet the 2010",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    classification criteria for RA, even in the presence of other characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Upper and lower extremity involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of both upper and lower extremities is a characteristic of RA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/19\">",
"     19",
"    </a>",
"    ]. The finding of both upper and lower extremity joint involvement is more predictive of RA than the involvement of either the upper or lower extremity alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assays for autoantibodies and acute phase reactants are helpful in the early diagnosis of RA. The most reliable early predictors of both chronic and erosive disease are the presence of high titer RF and ACPA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/19,20,22-26\">",
"     19,20,22-26",
"    </a>",
"    ]. The levels of these biomarkers are also important; the higher the level, the greater is the likelihood of disease chronicity, bone erosions, and joint destruction. [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/4,27\">",
"     4,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Rheumatoid factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic rheumatoid factor (RF) is an IgM autoantibody directed against the Fc region of IgG. RF is not pathognomonic for RA and frequently occurs in other disorders, such as connective tissue diseases and chronic infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42648?source=see_link\">",
"     \"Origin and utility of measurement of rheumatoid factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High RF titers (eg, &gt;50 international",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    discriminate well between RA and other types of inflammatory arthritis. As an example, in prospective follow-up of an inception cohort of 200 patients with inflammatory joint disease of less than three months' duration, the finding of a high RF titer was associated with a sensitivity of 96 percent for RA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/4\">",
"     4",
"    </a>",
"    ]. Given this high sensitivity and the broad overlap with ACPA (see below), an algorithm starting with RF testing, followed by testing for ACPA if RF &lt;50 international",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    is of very good diagnostic and prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/28\">",
"     28",
"    </a>",
"    ]. Indeed, such an algorithm was also proposed by the National Institute of Clinical Excellence (NICE) in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Anti-citrullinated protein antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-citrullinated protein antibodies (ACPA) are more specific but slightly less sensitive for RA than are positive RF assays [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/4,20\">",
"     4,20",
"    </a>",
"    ]. ACPA were originally described as anti-perinuclear factor and anti-keratin antibodies, and anti-Sa antibodies are also directed to a citrullinated protein. Both ACPA and RF are present in approximately one-half of patients with early arthritis who are diagnosed subsequently as having RA. High titer RF and ACPA overlap in approximately 60 percent of RA patients who are positive for either test [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/20\">",
"     20",
"    </a>",
"    ]. This figure increases to 80 percent if a lower threshold for RF is employed (typically greater than 14 international",
"    <span class=\"nowrap\">",
"     units/mL,",
"    </span>",
"    but the specific value depends upon the limits established in each individual laboratory) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-citrullinated peptide antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other types of autoantibodies have also been evaluated in RA, but their utility as markers for early diagnosis requires additional investigation. These autoantibodies include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anti-RA33 antibodies",
"     </li>",
"     <li>",
"      Anti-collagen antibodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These autoantibodies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2234?source=see_link\">",
"     \"Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Acute phase reactants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute phase reactants such as the erythrocyte sedimentation rate and serum C-reactive protein are typically elevated in early arthritis patients who are eventually determined to have RA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/17\">",
"     17",
"    </a>",
"    ]. However, there is considerable variability from patient to patient. This variability limits the predictive value of these test results in early diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/31\">",
"     31",
"    </a>",
"    ]. On the other hand, clinical disease activity and joint damage correlate well with acute phase reactant levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional radiography, magnetic resonance imaging (MRI), and other imaging techniques can also be helpful in diagnosing RA. The use of these techniques is discussed in detail separately; the following sections are limited to their use in early disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link&amp;anchor=H8594869#H8594869\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\", section on 'Evaluation for suspected RA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of erosions is strongly indicative of is but not specific for RA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/28\">",
"     28",
"    </a>",
"    ]. They can also occur in gout, psoriatic arthritis, and a number of other inflammatory joint conditions.",
"   </p>",
"   <p>",
"    In early RA, erosions seldom occur within the first three months of the onset of clinical disease. This was illustrated in a study of 55 such patients in whom erosions on plain radiographs were found in less than 10 percent at baseline compared with 64 percent at three-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/31\">",
"     31",
"    </a>",
"    ]. The yield may be higher with computed tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, the institution of therapy should not be postponed if erosions are absent but RA remains the likely diagnosis, given the importance of early intervention to prevent joint damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other imaging modalities, such as magnetic resonance imaging (MRI) and ultrasonography, have been evaluated for their utility in patients with RA. Both allow detection of synovitis, synovial effusions, and tenosynovitis even if clinically not apparent, in addition to joint damage. However, more outcomes data are needed before they can be broadly recommended for routine clinical use.",
"   </p>",
"   <p>",
"    MRI correlates highly with CT in the number and volume of erosions detected [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/35\">",
"     35",
"    </a>",
"    ]. MRI is preferred to CT for the purpose of joint imaging in RA because of the absence of radiation. However, MRI does not depict cartilage changes and may not distinguish early RA from systemic lupus erythematosus and Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasonography has been proposed as an alternate imaging modality for early detection of erosive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, further studies are needed to define its potential role in the diagnosis of early RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4392?source=see_link\">",
"     \"Musculoskeletal ultrasonography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone densitometry of the hand appears to be more sensitive than plain radiography for the detection of early demineralization in patients with early RA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/39\">",
"     39",
"    </a>",
"    ]. Additional studies are required before its use can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROBABILITY OF RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the limitations cited above and the increasing availability of highly effective therapies, there was significant interest in the development of new criteria for the diagnosis of early RA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/18,21,28,40,41\">",
"     18,21,28,40,41",
"    </a>",
"    ], resulting in the initial step of new 2010",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    classification criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The need for such criteria was underscored by several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/28,42\">",
"     28,42",
"    </a>",
"    ]. In a 2002 study, only 52 percent of RA patients diagnosed one year after presentation had fulfilled the 1987 ACR classification criteria at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/28\">",
"     28",
"    </a>",
"    ]. On the other hand, approximately 20 percent of patients who did not have RA satisfied those criteria at the time of presentation. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Classification criteria for RA'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The classification criteria for RA have been used by clinicians as an aid to the diagnosis of RA, although they were not designed or validated for that purpose. The score achieved using the 2010",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    classification criteria correlates with the probability of a patient&rsquo;s risk for developing persistent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erosive RA, although, in practice, some patients will be recognized having RA without meeting the classification criteria threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The 2010",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    criteria are shown in detail at:",
"    <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/classification/ra/ra_2010.asp\">",
"     www.rheumatology.org/practice/clinical/classification/ra/ra_2010.asp",
"    </a>",
"    (accessed September 21, 2010).",
"   </p>",
"   <p>",
"    The diagnosis of RA, and the classification criteria and their role in diagnosis, including in patients with early disease, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\", section on 'Classification criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link&amp;anchor=H8594876#H8594876\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint inflammation is a feature of many diseases other than RA. The differential diagnosis of RA depends upon the type of joint involvement",
"    <span class=\"nowrap\">",
"     (mono/oligo/polyarthritis;",
"    </span>",
"    <span class=\"nowrap\">",
"     large/small",
"    </span>",
"    joint arthritis), gender, age, geographical region, and many other factors. A brief summary of the differential diagnosis is included here (",
"    <a class=\"graphic graphic_table graphicRef51732 \" href=\"UTD.htm?40/21/41308\">",
"     table 2",
"    </a>",
"    ) and is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Viral arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint inflammation associated with viral infections such as that mediated by parvovirus B19 can be differentiated from RA by the self-limited character of the symptoms and signs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=see_link\">",
"     \"Specific viruses that cause arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Crystal diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crystal diseases such as gout and pseudogout sometimes mimic RA. However, they can usually be distinguished from RA by careful history, typical laboratory findings, characteristic radiographic features, and the detection of crystals in the synovial fluid examined under polarized light. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of gout\", section on 'Chronic tophaceous gout'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\", section on 'Pseudo-rheumatoid arthritis (\"chronic CPP crystal inflammatory arthritis\")'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Connective tissue diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Connective tissue diseases such as systemic lupus erythematosus (SLE) or polymyositis can cause an inflammatory polyarthritis that is similar to RA in its presentation. However, the pattern of organ system involvement beyond the joints, distinctive autoantibody profiles, and the absence of periarticular erosions help distinguish the arthritis of RA from that of SLE and other connective tissue diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23753?source=see_link&amp;anchor=H2#H2\">",
"     \"Musculoskeletal manifestations of systemic lupus erythematosus\", section on 'Arthritis and arthralgias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Seronegative spondyloarthropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The seronegative spondyloarthropathies are disorders that tend to involve the spine, have a host of potential extraarticular manifestations, and are not associated with the presence of RF or ACPA in the serum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=see_link\">",
"     \"Diagnosis and differential diagnosis of ankylosing spondylitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three major features of the seronegative spondyloarthropathies serve to distinguish them from RA. First, the arthritis of seronegative disorders is likely to be asymmetric compared with the typically symmetric involvement in RA. Second, the involvement of distal interphalangeal joints or the development of dactylitis (so-called &ldquo;sausage digits&rdquo;) in either the fingers or the toes is characteristic of seronegative spondyloarthropathies but not RA. Third, the lower extremities are more frequently involved than the upper extremities.",
"   </p>",
"   <p>",
"    The specific conditions within this category of inflammatory joint disease that must be considered are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ankylosing spondylitis &mdash; Patients with ankylosing spondylitis may present with peripheral joint involvement but eventually develop clinical evidence of inflammatory back disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link\">",
"       \"Clinical manifestations of ankylosing spondylitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reactive arthritis &mdash; Reactive arthritis is usually preceded by clinical evidence of a gastrointestinal or urogenital tract infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"       \"Reactive arthritis (formerly Reiter syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Psoriatic arthritis &mdash; Psoriatic arthritis may accompany or precede active psoriasis, and patients often have an immediate family member with a history of psoriasis. Psoriatic arthritis is more likely than RA to be asymmetric, to involve the distal interphalangeal joints, and to be associated with changes in the fingernails known as &ldquo;pitting&rdquo; (",
"      <a class=\"graphic graphic_picture graphicRef62855 \" href=\"UTD.htm?38/42/39599\">",
"       picture 1",
"      </a>",
"      ). However, the most frequent form of psoriatic arthritis has a similar pattern of joint involvement on presentation to seronegative rheumatoid arthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"       \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arthritis of inflammatory bowel disease &mdash; Arthritis associated with inflammatory bowel disease is generally accompanied by abdominal complaints. However, such bowel symptoms can be mild or nonspecific. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=see_link\">",
"       \"Arthritis associated with gastrointestinal disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute sarcoid arthritis, which predominantly affects the lower extremities, is typically a symmetric form of joint inflammation that spares the axial skeleton. Sarcoid arthropathy often affects the tissues around a joint in a &ldquo;periarthritis&rdquo; fashion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=see_link\">",
"     \"Sarcoid arthropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The L&ouml;fgren syndrome, a common mode of presentation of sarcoidosis, is characterized by a triad of ankle arthritis (or periarthritis), erythema nodosum, and bilateral hilar adenopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Lofgren's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Acute rheumatic fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute rheumatic fever can cause an inflammatory polyarthritis. However, the demographic and clinical features of joint involvement differ substantially from those of RA. Acute rheumatic fever is more likely to affect children than adults, and the arthritis associated with this disorder is typically migratory in nature. Polyarthritis can occur, but the joint inflammation in any single joint generally lasts not more than a week. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\", section on 'Arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Palindromic rheumatism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Finally, it should be borne in mind that RA, like some other chronic inflammatory diseases, can start in a rapidly remitting-relapsing, migratory fashion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features of rheumatoid arthritis\", section on 'Palindromic rheumatism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     EARLY RHEUMATOLOGY REFERRALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two sets of European expert panel recommendations regarding early referral of suspected RA have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/18,22\">",
"     18,22",
"    </a>",
"    ]. One suggests clinical suspicion of RA and rapid referral to a rheumatologist, if any of three characteristics are present; these are the presence of three or more swollen joints, pain with compression of the metatarsal phalangeal joints or metacarpophalangeal joints, and morning stiffness of more than 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/18\">",
"     18",
"    </a>",
"    ]. The other proposal generally suggests referral of patients with one or more swollen joints within six weeks of symptom onset, following careful history, physical, and laboratory examinations to exclude other diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/22\">",
"     22",
"    </a>",
"    ]. Such early referral to a specialist is important to ensure adequate and timely institution of disease modifying antirheumatic drugs, which should be started as soon as the diagnosis of RA is made [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18521/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early diagnosis of rheumatoid arthritis (RA) is critical to the prevention of long-term joint damage because of the availability of effective therapy and the knowledge that joint destruction occurs within two years of the onset of arthritis in the vast majority of patients and accumulates over time. For practical purposes, an early diagnosis of RA should be considered to be one rendered within three to six months of the onset of joint symptoms.",
"     </li>",
"     <li>",
"      The American College of Rheumatology (ACR) revised criteria for the classification of RA, issued in 1987, were developed in studies of patients with established RA. New criteria, published in 2010 by ACR and EULAR, have been developed, in large part, to improve the recognition of patients with early RA for inclusion in clinical studies but can aid in diagnosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification criteria for RA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Probability of RA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classic early RA is associated with a polyarthritis involving the small joints of the hands and feet, at least 60 minutes of morning stiffness, and symptoms that have persisted for at least six weeks. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RA is typically associated with symmetric joint involvement and involvement of both upper and lower extremities. However, exceptions to these rules are common in the early stages of RA. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assays for rheumatoid factor (RF) and (especially if RF is &lt;50 international",
"      <span class=\"nowrap\">",
"       units/mL)",
"      </span>",
"      for antibodies to citrullinated peptides and measurement of acute phase reactants should be performed in patients suspected of RA on the basis of historical features and physical examination findings. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain radiographs have a low sensitivity for joint erosions in early RA. Magnetic resonance imaging (MRI) studies are superior at detecting erosions early, but the precise role of MRI in the diagnosis and longitudinal management of patients with RA remains to be defined. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/1\">",
"      Smolen JS, Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 2004; 63:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/2\">",
"      Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/3\">",
"      Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/4\">",
"      Nell VP, Machold KP, Stamm TA, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005; 64:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/5\">",
"      van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with \"second-line\" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996; 124:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/6\">",
"      Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/7\">",
"      Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/8\">",
"      Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006; 54:2784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/9\">",
"      Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007; 56:3226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/10\">",
"      Masi AT. Articular patterns in the early course of rheumatoid arthritis. Am J Med 1983; 75:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/11\">",
"      Rantap&auml;&auml;-Dahlqvist S. Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 2005; 34:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/12\">",
"      Singh JA, Solomon DH, Dougados M, et al. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum 2006; 55:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/13\">",
"      Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/14\">",
"      Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/15\">",
"      Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/16\">",
"      Buchbinder R, Bombardier C, Yeung M, Tugwell P. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures' responsiveness to treatment in a randomized controlled trial. Arthritis Rheum 1995; 38:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/17\">",
"      van der Helm-van Mil AH, le Cessie S, van Dongen H, et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007; 56:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/18\">",
"      Emery P, Breedveld FC, Dougados M, et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002; 61:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/19\">",
"      Smolen JS, Breedveld FC, Eberl G, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995; 38:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/20\">",
"      Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/21\">",
"      Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/22\">",
"      Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/23\">",
"      Bukhari M, Lunt M, Harrison BJ, et al. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002; 46:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/24\">",
"      van Gaalen FA, van Aken J, Huizinga TW, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004; 50:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/25\">",
"      Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993; 32:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/26\">",
"      Harrison BJ, Symmons DP, Brennan P, et al. Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol 1996; 35:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/27\">",
"      Symmons DP. Classification criteria for rheumatoid arthritis--time to abandon rheumatoid factor? Rheumatology (Oxford) 2007; 46:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/28\">",
"      Machold KP, Stamm TA, Eberl GJ, et al. Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 2002; 29:2278.",
"     </a>",
"    </li>",
"    <li>",
"     National Collaborating Centre for Chronic Conditions. Rheumatoid arthritis: national clinical guideline for management and treatment in adults. London: Royal College of Physicians, February 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/30\">",
"      Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/31\">",
"      Machold KP, Stamm TA, Nell VP, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007; 46:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/32\">",
"      Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/33\">",
"      van Leeuwen MA, van Rijswijk MH, Sluiter WJ, et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997; 24:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/34\">",
"      D&oslash;hn UM, Ejbjerg BJ, Court-Payen M, et al. Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis metacarpophalangeal joints. Arthritis Res Ther 2006; 8:R110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/35\">",
"      D&oslash;hn UM, Ejbjerg BJ, Hasselquist M, et al. Rheumatoid arthritis bone erosion volumes on CT and MRI: reliability and correlations with erosion scores on CT, MRI and radiography. Ann Rheum Dis 2007; 66:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/36\">",
"      Boutry N, Hachulla E, Flipo RM, et al. MR imaging findings in hands in early rheumatoid arthritis: comparison with those in systemic lupus erythematosus and primary Sj&ouml;gren syndrome. Radiology 2005; 236:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/37\">",
"      &Oslash;stergaard M, Ejbjerg B, Szkudlarek M. Imaging in early rheumatoid arthritis: roles of magnetic resonance imaging, ultrasonography, conventional radiography and computed tomography. Best Pract Res Clin Rheumatol 2005; 19:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/38\">",
"      Keen HI, Brown AK, Wakefield RJ, Conaghan PG. MRI and musculoskeletal ultrasonography as diagnostic tools in early arthritis. Rheum Dis Clin North Am 2005; 31:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/39\">",
"      Haugeberg G, Green MJ, Conaghan PG, et al. Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. Ann Rheum Dis 2007; 66:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/40\">",
"      Aletaha D, Breedveld FC, Smolen JS. The need for new classification criteria for rheumatoid arthritis. Arthritis Rheum 2005; 52:3333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/41\">",
"      van der Helm-van Mil AH, Detert J, le Cessie S, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 2008; 58:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/42\">",
"      Harrison BJ, Symmons DP, Barrett EM, Silman AJ. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. American Rheumatism Association. J Rheumatol 1998; 25:2324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18521/abstract/43\">",
"      Smolen JS, Landew&eacute; R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7497 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18521=[""].join("\n");
var outline_f18_5_18521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION CRITERIA FOR RA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES OF EARLY RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Polyarticular involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Morning stiffness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Chronicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Joint tenderness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Symmetric arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Upper and lower extremity involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Rheumatoid factor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Anti-citrullinated protein antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROBABILITY OF RA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Viral arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Crystal diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Connective tissue diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Seronegative spondyloarthropathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Palindromic rheumatism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      EARLY RHEUMATOLOGY REFERRALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7497\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7497|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/42/39599\" title=\"picture 1\">",
"      Nail changes in psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7497|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/13/4316\" title=\"table 1\">",
"      ARA criteria for RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/21/41308\" title=\"table 2\">",
"      Characteristics estab RA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=related_link\">",
"      Arthritis associated with gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=related_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=related_link\">",
"      Clinical manifestations of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=related_link\">",
"      Diagnosis and differential diagnosis of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2234?source=related_link\">",
"      Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23753?source=related_link\">",
"      Musculoskeletal manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4392?source=related_link\">",
"      Musculoskeletal ultrasonography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42648?source=related_link\">",
"      Origin and utility of measurement of rheumatoid factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=related_link\">",
"      Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=related_link\">",
"      Sarcoid arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_5_18522="Overview of the use of estrogen-progestin contraceptives";
var content_f18_5_18522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the use of estrogen-progestin contraceptives",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/5/18522/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/5/18522/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/5/18522/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/5/18522/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/5/18522/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/5/18522/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/5/18522/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/5/18522/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/5/18522/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral contraceptives (OCs) are a reliable form of contraception and have noncontraceptive benefits, as well. Furthermore, the decrease in both estrogen and progestin content in the last decade (so-called second generation OCs) has led to a reduction in both side effects and cardiovascular complications&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, these preparations are a reasonable contraceptive option for many women. While the Food and Drug Administration had previously set upper age limits for OC use as 35 years for smokers and 40 years for nonsmokers, all references to age limits were removed in 1989 for healthy, nonsmoking women. Thus, OCs can be given until menopause in such women.",
"   </p>",
"   <p>",
"    This topic will review the general principles of the use of combined estrogen-progestin oral contraceptives, including pharmacology, mechanisms of action, indications, contraindications, efficacy, and the different preparations that are available. Progestin-only oral contraceptives, the side effects that may be associated with OCs, other forms of estrogen-progestin contraception, and the topic of contraception in general are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=see_link\">",
"     \"Progestin-only pills (minipills) for contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41127?source=see_link\">",
"     \"Transdermal contraceptive patch\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discovery in 1938 that addition of an ethinyl group to estradiol resulted in both an orally active estrogen compound and a dramatic increase in estrogenic potency was a major advance in steroid biochemistry. This compound, known as ethinyl estradiol, is the estrogen in nearly all OCs currently used.",
"   </p>",
"   <p>",
"    Soon thereafter, ethinyl substitution of testosterone also was found to result in an orally active compound (ethisterone). Removal of the carbon at the C-19 position of ethisterone changed it from an androgen to a progestin. This finding resulted in the development of a class of progestins referred to as 19-nortestosterone derivatives. Included in this class are commonly used progestins such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    . Ethynodiol diacetate, another progestin in this category, also has significant estrogenic activity (",
"    <a class=\"graphic graphic_table graphicRef87416 \" href=\"UTD.htm?23/23/23931\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    All of these testosterone-derived progestins bind to the androgen receptor and have some residual androgenic activity. The adverse metabolic effects of OCs, such as the reduction in serum high-density lipoprotein (HDL) cholesterol concentrations, are the result of the androgenic activity of the progestin. New progestins have been developed with less androgenic activity (",
"    <a class=\"graphic graphic_table graphicRef87416 \" href=\"UTD.htm?23/23/23931\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H27\">",
"     'New progestins'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While OCs have several mechanisms of action, the most important mechanism for providing contraception is estrogen-induced inhibition of the midcycle surge of gonadotropin secretion, so that ovulation does not occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=see_link\">",
"     \"Physiology of the normal menstrual cycle\"",
"    </a>",
"    .) Combination OCs are potent in this regard, but progestin-only pills are not.",
"   </p>",
"   <p>",
"    Another potential mechanism of contraceptive action is suppression of gonadotropin secretion during the follicular phase of the cycle, thereby preventing follicular maturation. However, a substantial number of women develop follicles while taking an OC that contains 20 to 35 mcg of ethinyl estradiol&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians often recommend that back-up contraception be used in the first cycle of OC use, due to concern that early follicular development could result in breakthrough ovulation (most package inserts recommend starting the pill on the first Sunday after menses, which could be as late as day 7). In a study of 140 women randomly assigned to start their oral contraceptive (containing 30 mcg ethinyl",
"    <span class=\"nowrap\">",
"     estradiol/day)",
"    </span>",
"    on day 1, 4, or 7 of menses, follicular development (diameter &gt;13 mm) was more common with the later start days (10.3, 17.2, and 44.4 percent for days 1, 4, and 7, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/4\">",
"     4",
"    </a>",
"    ]. However, rates of ovulation were no different in the three groups (7, 3, and 0 percent, respectively). Thus, back-up contraception might not be necessary in the first month of OC use, but a larger study is needed before changing clinical practice.",
"   </p>",
"   <p>",
"    This observation highlights the importance of preventing the midcycle surge of gonadotropin secretion.",
"   </p>",
"   <p>",
"    Other estrogenic mechanisms of action include suppression of ovarian steroid production, due to suppression of gonadotropin secretion, and a possible decrease in responsiveness of the pituitary to gonadotropin-releasing hormone.",
"   </p>",
"   <p>",
"    Progestin-related mechanisms also contribute to the contraceptive effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=see_link&amp;anchor=H2#H2\">",
"     \"Progestin-only pills (minipills) for contraception\", section on 'Mechanism of action'",
"    </a>",
"    .) These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Effects on the endometrium, rendering it less suitable for implantation",
"     </li>",
"     <li>",
"      Alterations in cervical mucus, which becomes less permeable to penetration by sperm",
"     </li>",
"     <li>",
"      Impairment of normal tubal motility and peristalsis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Use in hyperandrogenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination OCs are useful for the treatment of women with hyperandrogenism (most often due to polycystic ovary syndrome).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     Levonorgestrel",
"    </a>",
"    -containing preparations may aggravate hyperandrogenism and should be avoided. Many OCs with less androgenic progestins are available (",
"    <a class=\"graphic graphic_table graphicRef78782 \" href=\"UTD.htm?35/3/35900\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"     \"Treatment of hirsutism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/17/27928?source=see_link\">",
"     \"Use of combination estrogen-progestin contraceptives in the treatment of hyperandrogenism and hirsutism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44599?source=see_link&amp;anchor=H4#H4\">",
"     \"Hormonal therapy for women with acne vulgaris\", section on 'Oral contraceptives'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the beneficial effects of an OC in women with hyperandrogenism are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inhibition of gonadotropin secretion, which results in increased binding of androgens and thereby a decrease in ovarian androgen secretion",
"     </li>",
"     <li>",
"      An increase in serum SHBG concentrations, which results in a decrease in serum free androgen concentrations",
"     </li>",
"     <li>",
"      Inhibition of adrenal androgen secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/5\">",
"       5",
"      </a>",
"      ]; the mechanism of the last effect is not well understood",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Use in other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many other indications for the use of OCs other than contraception and hyperandrogenism. These include the treatment of dysmenorrhea, menorrhagia, other menstrual cycle disorders such as hypothalamic amenorrhea, and as hormone replacement in women with primary hypogonadism. OCs have also been used for the treatment of the premenstrual dysphoric disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=see_link\">",
"     \"Treatment of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Screening requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal contraception can be safely provided after a careful medical history and blood pressure measurement. While breast exams, pap smears, and screening for sexually transmitted diseases are important, most groups, including the American College of Obstetricians, the World Health Organization, and the Royal College of Obstetricians and Gynecologists, agree that these procedures are not necessary before a first prescription for OCs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/6\">",
"     6",
"    </a>",
"    ]. Documentation of body mass index (BMI) prior to starting OCs is also suggested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCs can be started at any time during the cycle. The preferred approach is the Quick Start method in which the woman begins taking OCs on the day that she is given the prescription, as long as pregnancy is reasonably excluded. An alternative is the Sunday Start approach where the woman starts the pill on the first Sunday after her period begins. These approaches are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of contraception\", section on 'Initiation and administration of combined OCs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A follow-up visit should be scheduled in one year; however, a three-month follow-up visit can be useful to measure blood pressure and discuss satisfaction and side effects. Continuation of the contraceptive method is enhanced if the patient receives a prescription for a full year of pills [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3033285\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of absolute and relative contraindications to the use of OCs, as well as medical conditions that may affect contraceptive choice; all are summarized in the World Health Organization and Centers for Disease Control tables that are described in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175457713\">",
"    <span class=\"h3\">",
"     World Health Organization tables",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) has published comprehensive tables of medical conditions and personal characteristics that may affect contraceptive choice (hormonal contraception and IUDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These tables can be found online and are summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Personal characteristics (",
"      <a class=\"graphic graphic_table graphicRef82680 \" href=\"UTD.htm?20/51/21311\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cardiovascular disease (",
"      <a class=\"graphic graphic_table graphicRef65586 \" href=\"UTD.htm?39/25/40350\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Headache and epilepsy (",
"      <a class=\"graphic graphic_table graphicRef62351 \" href=\"UTD.htm?36/61/37853\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Depression (",
"      <a class=\"graphic graphic_table graphicRef61848 \" href=\"UTD.htm?1/1/1052\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reproductive",
"      <span class=\"nowrap\">",
"       tract/breast",
"      </span>",
"      abnormalities, cancer, infections (",
"      <a class=\"graphic graphic_table graphicRef60832 \" href=\"UTD.htm?33/28/34255\">",
"       table 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      HIV (",
"      <a class=\"graphic graphic_table graphicRef75345 \" href=\"UTD.htm?38/20/39245\">",
"       table 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gastrointestinal disease (",
"      <a class=\"graphic graphic_table graphicRef55954 \" href=\"UTD.htm?5/40/5774\">",
"       table 9",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thalassemia and sickle cell anemia (",
"      <a class=\"graphic graphic_table graphicRef78542 \" href=\"UTD.htm?22/49/23324\">",
"       table 10",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diabetes and thyroid disease (",
"      <a class=\"graphic graphic_table graphicRef69329 \" href=\"UTD.htm?19/34/20013\">",
"       table 11",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Drugs and drug interactions (",
"      <a class=\"graphic graphic_table graphicRef54244 \" href=\"UTD.htm?36/54/37741\">",
"       table 12",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rheumatological issues (",
"      <a class=\"graphic graphic_table graphicRef65563 \" href=\"UTD.htm?41/14/42220\">",
"       table 13",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &ldquo;Initiation&rdquo; recommendations apply to women in whom the medical condition precedes initiation of the method; &ldquo;continuation&rdquo; recommendations apply to women who develop the medical condition while using the method.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175457720\">",
"    <span class=\"h3\">",
"     CDC tables",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2010, the Centers for Disease Control (CDC) modified the WHO tables for medical eligibility criteria for contraceptive use [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/9\">",
"     9",
"    </a>",
"    ]. Selected WHO recommendations were adapted for US clinicians and patients, the number of medical conditions was expanded and recommendations added, and contraceptive methods not available in the US were removed. The CDC tables are included here (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 14",
"    </a>",
"    ) and are available on the",
"    <a class=\"external\" href=\"file://www.cdc.gov/Mmwr/preview/mmwrhtml/rr59e0528a13.htm\">",
"     CDC website",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Based upon the CDC table, some of the medical conditions that represent an unacceptable health risk if a combined estrogen-progestin oral contraceptive were initiated include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &ge;35 years and smoking &ge;15 cigarettes per day",
"     </li>",
"     <li>",
"      Multiple risk factors for arterial cardiovascular",
"      <strong>",
"      </strong>",
"      disease (such as older age, smoking, diabetes, and hypertension)",
"     </li>",
"     <li>",
"      Hypertension (systolic &ge;160 mmHg or diastolic &ge;100 mmHg)",
"     </li>",
"     <li>",
"      Venous thromboembolism",
"     </li>",
"     <li>",
"      Known thrombogenic mutations",
"     </li>",
"     <li>",
"      Known ischemic heart disease",
"     </li>",
"     <li>",
"      History of stroke",
"     </li>",
"     <li>",
"      Complicated valvular heart disease (pulmonary hypertension, risk for atrial fibrillation, history of subacute bacterial endocarditis)",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus (positive or unknown antiphospholipid antibodies)",
"     </li>",
"     <li>",
"      Migraine with aura at any age",
"     </li>",
"     <li>",
"      Breast cancer",
"     </li>",
"     <li>",
"      Cirrhosis",
"     </li>",
"     <li>",
"      Hepatocellular adenoma or malignant hepatoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When taken properly, OCs are a very effective form of contraception. Although the theoretical failure rate is 0.1 percent, the actual failure rate is 8 percent due primarily to missed pills or failure to resume therapy after the seven-day pill-free interval (",
"    <a class=\"graphic graphic_table graphicRef70218 \" href=\"UTD.htm?12/56/13197\">",
"     table 15",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Missed pills",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a single pill is missed anywhere in the packet, the forgotten pill needs to be taken when noticed and the next pill is taken when it is due, which may mean taking two pills on the same day. No additional contraception is required.",
"   </p>",
"   <p>",
"    Back-up contraception is generally needed if two or more consecutive pills are missed. Although WHO states that no back-up or emergency contraception is needed unless three or more 30 to 35 mcg ethinyl estradiol pills have been forgotten (or two or more 20 to 25 mcg pills) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/10\">",
"     10",
"    </a>",
"    ], other experts recommend back-up contraception after missing two pills of any dose of combined oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. We agree with the simpler recommendation that back-up contraception be used for seven days after two missed active hormonal pills, regardless of dose. In addition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women should take one of the missed active (hormonal) pills as soon as possible and then continue taking one pill each day as prescribed. Depending on when she remembers her missed pill, she may take two pills on the same day.",
"     </li>",
"     <li>",
"      If the two or more pills are missed in the first week of the cycle and unprotected intercourse occurs during this week, use of emergency contraception could decrease the risk of pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Also, if",
"    <strong>",
"     seven or more",
"    </strong>",
"    pills are left in the pack after the last missed pill, she should finish the pack and have the usual seven day break. If",
"    <strong>",
"     less than seven",
"    </strong>",
"    pills are left in the pack after the missed pill, she should finish the pack and begin a new pack the next day (omit hormone-free days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effect of weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;While some epidemiologic studies suggest that being overweight or obese may increase the risk of becoming pregnant while on oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], another reported that the association was attenuated after adjustment for age,",
"    <span class=\"nowrap\">",
"     race/ethnicity,",
"    </span>",
"    and parity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/15\">",
"     15",
"    </a>",
"    ]. Clinical trial data are somewhat limited [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/16\">",
"     16",
"    </a>",
"    ]. In a low-dose (25 mcg) oral contraceptive trial that enrolled 876 overweight (BMI &ge;25",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    and 1934 normal women (BMI &lt;25",
"    <span class=\"nowrap\">",
"     kg/m2),",
"    </span>",
"    those in the overweight group had a higher risk of becoming pregnant (relative risk 1.39) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/17\">",
"     17",
"    </a>",
"    ]. One possible explanation for the higher failure rate among overweight women would be incomplete suppression of the hypothalamic-pituitary-ovarian axis, resulting in follicular development and ovulation. However, in a separate trial of 96 normal and 54 obese women (BMI &lt;25 or &ge;30",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    respectively), rates of follicular development and ovulation (as assessed by pelvic ultrasound) were similar in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/18\">",
"     18",
"    </a>",
"    ]. Inconsistent or nonuse of the pill, but not obesity, was associated with ovulation. Thus, for overweight or obese women who take oral contraceptives, compliance may be particularly important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4233?source=see_link\">",
"     \"Contraception counseling for obese women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NONCONTRACEPTIVE BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to providing menstrual cycle regularity and high contraceptive efficacy, estrogen-progestin contraceptives are used as treatment for or have been associated with noncontraceptive benefits for the following conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Menstrual cycle disorders",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Menorrhagia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=see_link\">",
"       \"Hormonal contraception for suppression of menstruation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dysmenorrhea (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28233?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of primary dysmenorrhea in adult women\", section on 'Hormonal contraception'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD; continuous pills or pills with shortened pill-free interval); however, the pill is",
"      <strong>",
"       not",
"      </strong>",
"      considered a first-line therapy for",
"      <span class=\"nowrap\">",
"       PMS/PMDD",
"      </span>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=see_link\">",
"       \"Treatment of premenstrual syndrome and premenstrual dysphoric disorder\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prevention of menstrual migraine (continuous pill) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35433?source=see_link&amp;anchor=H9#H9\">",
"       \"Estrogen-associated migraine\", section on 'Preventive therapies'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hyperandrogenism",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acne (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44599?source=see_link\">",
"       \"Hormonal therapy for women with acne vulgaris\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hirsutism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"       \"Treatment of hirsutism\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gynecologic disorders",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bleeding due to leiomyomas (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of treatment of uterine leiomyomas (fibroids)\", section on 'Estrogen-progestin contraceptives'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pelvic pain due to endometriosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of the treatment of endometriosis\", section on 'Estrogen-progestin oral contraceptives'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cancer risk reduction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased risk of endometrial cancer and ovarian cancer; data are conflicting on whether there is a similar reduction in risk in BRCA1 or BRCA2 ovarian cancers (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H23#H23\">",
"       \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Hormonal contraceptives'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"       \"Epithelial ovarian cancer: Pathology\"",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Decreased risk of colon cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ovarian cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hormonal contraceptives are often prescribed to suppress large functional ovarian cysts, a systematic review of available data concluded that functional cysts do not regress more quickly with estrogen-progestin contraceptive therapy when compared with expectant management [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/19,22\">",
"     19,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     USE DURING LACTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization and the American College of Obstetricians and Gynecologists (ACOG) have made recommendations for nonhormonal and hormonal contraception during lactation. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link&amp;anchor=H20#H20\">",
"     \"Principles of medication use during lactation\", section on 'Contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolism of OCs is accelerated by any drug that increases liver microsomal enzyme activity such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"     griseofulvin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    . As a result, the contraceptive efficacy of an OC is likely to be decreased in women taking these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) suggests that women taking anticonvulsants including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , barbiturates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    should not use hormonal contraception (with the exception of depo-medroxyprogesterone acetate) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/25\">",
"     25",
"    </a>",
"    ]. They add, however, that hormonal contraception is reasonable if the patient understands the risks and cannot use other methods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .) The WHO also concludes that hormonal contraception is reasonable for women on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"     griseofulvin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anticonvulsants that do not appear to reduce contraceptive efficacy include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/22/26982?source=see_link\">",
"     tiagabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/26\">",
"     26",
"    </a>",
"    ]. However, in one study of women with epilepsy, estrogen-progestin OCs decreased plasma lamotrigine concentrations by 45 to 60 percent, raising concerns about adequate seizure control if an OC and lamotrigine are used in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    is the only antibiotic proven to decrease serum ethinyl estradiol and progestin levels in women taking oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/23\">",
"     23",
"    </a>",
"    ]; a nonhormonal contraceptive method is recommended in these women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/28\">",
"     28",
"    </a>",
"    ]. Rifampin may also decrease the effectiveness of the transdermal (Ortho Evra) and vaginal ring (NuvaRing) preparations; an alternate form of contraception should be used in this situation, as well.",
"   </p>",
"   <p>",
"    In spite of anecdotal reports of oral contraceptive failure, other antibiotics have",
"    <strong>",
"     not",
"    </strong>",
"    been proven to affect the pharmacokinetics of ethinyl estradiol [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. For women taking antibiotics other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    with oral contraceptives, back-up contraception is not required.",
"   </p>",
"   <p>",
"    Vaginal miconazole suppositories and creams do not appear to affect serum steroid levels in women using the contraceptive vaginal ring [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;St. John's wort induces cytochrome P450, which may increase OC metabolism and reduce therapeutic efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/34\">",
"     34",
"    </a>",
"    ]. Two small clinical trials of women on oral contraceptives reported an increase in breakthrough bleeding with the addition of St. John's Wort [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Although serum progesterone concentrations were unchanged, concerns remain that contraceptive efficacy could be reduced with this combination.",
"   </p>",
"   <p>",
"    The opposite effect, a decrease in metabolism of the administered estrogen, can occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/37\">",
"     37",
"    </a>",
"    ] and possibly grapefruit juice [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], resulting in a higher than expected serum concentration of ethinyl estradiol. Whether this results in untoward effects is unclear.",
"   </p>",
"   <p>",
"    Limited data suggest that grapefruit juice may inhibit metabolism of exogenous ethinyl estradiol and 17-beta estradiol, resulting in higher serum concentrations.",
"   </p>",
"   <p>",
"    Drug interactions between oral contraceptives and many of the drugs used to treat HIV infection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=see_link&amp;anchor=H26#H26\">",
"     \"HIV and women\", section on 'Choice of contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PREPARATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of oral contraceptive pills: combination pills that contain both estrogen and progestin, and the progestin-only pill (also referred to as the \"mini-pill\") (",
"    <a class=\"graphic graphic_table graphicRef69223 \" href=\"UTD.htm?10/59/11184\">",
"     table 16",
"    </a>",
"    ). Progestin-only pills, which are associated with more breakthrough bleeding than combination pills, are rarely prescribed except in lactating women. In contrast, parenteral forms of progestin-only contraception are commonly prescribed, particularly in women who cannot take estrogen (",
"    <a class=\"graphic graphic_table graphicRef60293 \" href=\"UTD.htm?7/15/7419\">",
"     table 17",
"    </a>",
"    ). Progestin-only contraceptives (oral, injectables, and intrauterine devices) are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=see_link\">",
"     \"Progestin-only pills (minipills) for contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combination pills are packaged in 21-day or 28-day cycles. The last seven pills of a 28-day pack are placebo pills, which are thought by some to improve patient compliance, although this has never been proven.",
"   </p>",
"   <p>",
"    A chewable formulation (Femcon Fe) is available with 21 tablets containing ethinyl estradiol (35 mcg) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    (0.4 mg), and seven tablets containing only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7798?source=see_link\">",
"     ferrous fumarate",
"    </a>",
"    (75 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150022643\">",
"    <span class=\"h2\">",
"     Mono- versus multiphasic",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several types of combination pills. Monophasic pills contain the same dose of estrogen and progestin in each of the 21 hormonally active pills. Attempts to lower the total dose of steroids have resulted in the formulation of low dose monophasic pills containing a lower daily dose of both the estrogen and progestin components. While early OC preparations contained as much as 80 to 100 mcg of ethinyl estradiol, the current pills contain on average 30 to 35 mcg. Pills containing less than 50 mcg of ethinyl estradiol have been referred to as \"low-dose\" pills.",
"   </p>",
"   <p>",
"    Other \"multiphasic\" preparations were introduced in the late 1970s and 1980s in an attempt to further lower the total steroid dose. An example of a biphasic pill is Ortho",
"    <span class=\"nowrap\">",
"     10/11",
"    </span>",
"    which contains a fixed dose of 35 mcg of ethinyl estradiol and an increasing dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    : 0.5 mg for 10 days and 1.0 mg for 11 days. Triphasic preparations contain varying doses of progestin or estrogen plus progestin across the 21 days. One multiphasic preparation is an \"estrophasic\" oral contraceptive (Estrostep) that contains a fixed dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    (1 mg) and a gradually increasing dose of ethinyl estradiol (20 mcg on cycle days 1 to 5, 30 mcg on days 6 to 12, and 35 mcg on days 13 to 21) in an effort to minimize estrogen-related side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/41\">",
"     41",
"    </a>",
"    ]. Cyclessa is a triphasic preparation containing 25 mcg of ethinyl estradiol with increasing doses of desogestrel (100, 125, and 150 mcg days 1 to 7, 8 to 14, and 15 to 21, respectively). While these multiphasic regimens slightly decrease total steroid content over the month, they have no proven clinical advantage over monophasic preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     Cyproterone acetate",
"    </a>",
"    , a progestin and androgen receptor antagonist, is not available in the United States, but is available in Europe and Canada as a combination oral contraceptive (Diane) containing ethinyl estradiol and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone",
"    </a>",
"    acetate. This preparation is often prescribed for acne or hirsutism (",
"    <a class=\"graphic graphic_table graphicRef87416 \" href=\"UTD.htm?23/23/23931\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hormone-containing contraceptives are also available as an injection, implant, transdermal patch, and vaginal ring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150022959\">",
"    <span class=\"h2\">",
"     Estrogen preparation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150022978\">",
"    <span class=\"h3\">",
"     Type",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ethinyl estradiol is the estrogen in nearly all currently used OCs. However, a preparation containing estradiol valerate is available combined with a new progestin (Natazia [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/14/22759?source=see_link\">",
"     estradiol-dienogest",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/43\">",
"     43",
"    </a>",
"    ]. This is the first four-phase oral contraceptive available; the four phases have varying doses of estradiol valerate (1, 2, or 3 mg) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27366?source=see_link\">",
"     dienogest",
"    </a>",
"    (0, 2 or 3 mg). Natazia has 26 pills with hormones and two pills without hormones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150022985\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard dose OCs contain 30 to 35 mcg of ethinyl estradiol.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h4\">",
"     20 to 25 mcg",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many preparations containing only 20 mcg of ethinyl estradiol are available (",
"    <a class=\"graphic graphic_table graphicRef69223 \" href=\"UTD.htm?10/59/11184\">",
"     table 16",
"    </a>",
"    ). A 25 mcg preparation is also available (Tri-Cyclen Lo) with norgestimate 180 mcg days 1 to 7, 215 mcg days 8 to 14, and 250 mcg days 15 to 21 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contraceptive efficacy appears to be similar with oral contraceptives containing 20 mcg ethinyl estradiol when compared with pills with higher doses of estrogen, but data are somewhat limited [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breakthrough bleeding may be more common with the 20 mcg pills when compared with higher dose pills. However, in a systematic review, many of the clinical trials compared oral contraceptives containing different types of progestins [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/45\">",
"     45",
"    </a>",
"    ]. As a result, it is unclear whether the higher frequency of bleeding is due to the lower estrogen dose or to different progestin types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H627283998\">",
"    <span class=\"h4\">",
"     Perimenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;These lower dose pills are often used for nonsmoking, perimenopausal women who desire contraception, but who also have irregular or heavy menses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hormonally related symptoms that impair quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/46\">",
"     46",
"    </a>",
"    ]. These preparations provide more than enough estrogen to relieve vasomotor flushes (which often begin during the perimenopausal transition). One problem that perimenopausal women often experience when taking oral contraceptives is recurrence of hot flushes and premenstrual mood disturbances during the seven-day pill-free interval. One preparation, Mircette, contains 10 mcg of ethinyl estradiol on five of the seven \"placebo\" days. This preparation reduces flushes and mood symptoms when compared with seven days of placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of menopausal symptoms with hormone therapy\", section on 'Use of oral contraceptives during the menopausal transition'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Oral contraception should be avoided altogether in obese perimenopausal women, as the risk of venous thromboembolism increases with both age and body mass index; risk appears to be twice as high as for non-obese women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H11#H11\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Venous thromboembolic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150023028\">",
"    <span class=\"h4\">",
"     10 mcg",
"    </span>",
"    &nbsp;&mdash;&nbsp;An even lower dose preparation, Lo Loestrin Fe, containing only 10 mcg of ethinyl estradiol is now available. It has a 28-day dosing schedule: 24 tablets containing 10 mcg ethinyl estradiol and 1 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    , two tablets containing only 10 mcg ethinyl estradiol, and two tablets containing 75 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7798?source=see_link\">",
"     ferrous fumarate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/48\">",
"     48",
"    </a>",
"    ]. In a one year, open-label, unpublished study of over 1000 women ages 18 to 35, the pregnancy rate was 2.92 pregnancies per 100 women-years of use (95% CI 1.94-4.21) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/48\">",
"     48",
"    </a>",
"    ]. This included women who did not take the pill correctly. This failure rate is similar to what is typically seen with higher dose pills. Women with a body mass index &gt;35",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    were not studied, so the contraceptive efficacy of this pill in severely obese women is unknown.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     New progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A progestin with pure progestational activity would be ideal because the androgenic activity is not needed for contraception and it increases side effects and metabolic complications. More selective progestins have been developed. They include norgestimate, desogestrel, and gestodene (",
"    <a class=\"graphic graphic_table graphicRef78782 \" href=\"UTD.htm?35/3/35900\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87416 \" href=\"UTD.htm?23/23/23931\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These newer progestins are 19-nortestosterone derivatives, but they have some structural modifications that lower their androgen activity. Norgestimate (eg, Ortho-Cyclen or Tri-Cyclen) and desogestrel (eg, Desogen or Ortho-Cept) appear to be the least androgenic compounds in this class; these drugs are available in the United States, while gestodene is not (",
"    <a class=\"graphic graphic_table graphicRef87416 \" href=\"UTD.htm?23/23/23931\">",
"     table 1",
"    </a>",
"    ). Although the new progestins bind to the androgen receptor, the affinity is low, and they have little effect on serum sex hormone-binding globulin (SHBG) concentrations (which are lowered by androgens and raised by estrogens) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. It is important to note that in many studies of the new progestins, the comparison progestin was",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/51\">",
"     51",
"    </a>",
"    ], which is the most androgenic of the older progestins. The new progestins are not much less androgenic than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The contraceptive efficacy of OCs containing the new progestins (so-called third-generation OCs) is similar to that of the older formulations. In addition, when compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -containing pills, the newer OCs have less of an effect on carbohydrate and lipid metabolism and are more effective in reducing acne and hirsutism in hyperandrogenic women. They are, therefore, a good option for women who have difficulty tolerating or have metabolic complications with an older OC (",
"    <a class=\"graphic graphic_table graphicRef87416 \" href=\"UTD.htm?23/23/23931\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/17/27928?source=see_link\">",
"     \"Use of combination estrogen-progestin contraceptives in the treatment of hyperandrogenism and hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these potential advantages, there have been concerns about the safety of the newer progestins. Several large epidemiologic studies reported an increased risk of deep venous thrombosis with the use of these progestins, compared with earlier progestins [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/52\">",
"     52",
"    </a>",
"    ]. A similar increase in risk has been reported with oral contraceptives containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/53\">",
"     53",
"    </a>",
"    ]. However, this area remains controversial; the third generation pills continue to be widely used (",
"    <a class=\"graphic graphic_table graphicRef87416 \" href=\"UTD.htm?23/23/23931\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H11#H11\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Venous thromboembolic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Antiandrogenic progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestin preparations have been developed that have mild antiandrogenic activity. These include a compound derived from testosterone (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27366?source=see_link\">",
"     Dienogest",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/54\">",
"     54",
"    </a>",
"    ] and a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    analog (Drospirenone) (",
"    <a class=\"graphic graphic_table graphicRef87416 \" href=\"UTD.htm?23/23/23931\">",
"     table 1",
"    </a>",
"    ). Dienogest-containing OCs are available in combination with ethinyl estradiol and estradiol valerate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drospirenone (DRSP) is derived from 17 alpha-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    ; it has progestogenic, antiandrogenic, and antimineralocorticoid activity. Monophasic oral contraceptives containing either 20 or 30 mcg of ethinyl estradiol (EE) with 3 mg of DSRP (Yaz and Yasmin) are available. Generic preparations are also available. The 20 mcg preparation has a four day pill-free interval as opposed to the standard seven-day interval. There are concerns about an excess risk of venous thromboembolism with preparations containing drospirenone when compared with those containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H11#H11\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Venous thromboembolic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a two-year trial in 900 women randomly assigned to receive either the 30 mcg",
"    <span class=\"nowrap\">",
"     EE/3mg",
"    </span>",
"    DSRP pill or a 30",
"    <span class=\"nowrap\">",
"     mcg/150",
"    </span>",
"    mcg desogestrel preparation, contraceptive efficacy was similar, but mean body weight was lower than baseline with the drospirenone pill, presumably due to its antimineralocorticoid effect [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drospirenone is also effective for acne and hirsutism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/56,57\">",
"     56,57",
"    </a>",
"    ], but there is no evidence that it is more effective than other OCs for hyperandrogenic symptoms. Although drospirenone is an antiandrogen, it is a very weak one; 3 mg is equivalent to approximately 25 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The lower estrogen dose preparation (20 mcg ethinyl",
"    <span class=\"nowrap\">",
"     estradiol/drospirenone",
"    </span>",
"    3 mg) appears to be more effective than placebo for treating the premenstrual symptoms associated with premenstrual dysphoric disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=see_link\">",
"     \"Treatment of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although drospirenone has potential potassium-sparing effects (due to its antimineralocorticoid activity), women taking OCs containing drospirenone are no more likely to develop hyperkalemia than women taking other OC preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Current package labeling recommends potassium monitoring in the first month for women who take additional medications that predispose to hyperkalemia (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    , nonsteroidal antiinflammatory drugs) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/60\">",
"     60",
"    </a>",
"    ]. However, in one study, short-term coadministration of an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/62/42985?source=see_link\">",
"     ethinyl estradiol-drospirenone",
"    </a>",
"    OC with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    was associated with the same mean serum potassium and same low rate of serum potassium values above 5.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    as indomethacin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Shorter pill-free interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the original oral contraceptive was first introduced in 1960, most birth control pill formulations have had 21 days of hormonally active pills followed by seven days of placebo pills. More recently, extended-cycle and continuous hormone regimens have gained popularity. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Continuous pill'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, a number of formulations with 24 days of hormone pills and only four days of placebo pills are now available. It is hoped that contraceptive failures and side effects will be minimized with this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Continuous pill",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous or extended-cycle oral contraceptive regimens (where only active hormone pills are taken, ie, no placebo pills are used) have been used by clinicians for the treatment of a number of disorders including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endometriosis &mdash; The strategy with this approach is to induce decidualization and subsequent atrophy of endometrial tissue. This regimen may be as effective as a GnRH agonist for pain control. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link\">",
"       \"Overview of the treatment of endometriosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=see_link\">",
"       \"Hormonal contraception for suppression of menstruation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Premenstrual dysphoric disorder &mdash; To reduce symptoms of premenstrual dysphoric disorder (PMDD) by avoiding hormonal fluctuations. The effectiveness of this regimen for PMDD has not been studied in clinical trials. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=see_link\">",
"       \"Treatment of premenstrual syndrome and premenstrual dysphoric disorder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For lifestyle reasons, many women without any underlying disease or disorder prefer to take the pill continuously to minimize the frequency of menses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other therapies that suppress menstruation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=see_link\">",
"     \"Hormonal contraception for suppression of menstruation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extended-cycle preparations include seven-day intervals of placebo administration approximately every three months. One example is Seasonale, which has a 91-day cycle (84 days of active hormone [ethinyl estradiol 30 mcg and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    0.15 mg] and seven days of placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/62\">",
"     62",
"    </a>",
"    ]. A similar preparation, Seasonique, contains the same active hormones as Seasonale on days 1 through 84, but days 85 through 91 contain a small dose of ethinyl estradiol (10 mcg) instead of placebo.",
"   </p>",
"   <p>",
"    A preparation (Lybrel, 20 mcg ethinyl estradiol with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    0.09 mg) designed to be taken every day with no placebo phase is also available.",
"   </p>",
"   <p>",
"    Contraceptive efficacy appears to be the same with extended regimens as with cyclic regimens. Breakthrough bleeding is a common problem with continuous regimens in early cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/63-65\">",
"     63-65",
"    </a>",
"    ], but the frequency decreases over time and becomes similar to that for cyclic regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. Menstrual cramps and premenstrual symptoms appear to be decreased with continuous, compared with cyclic, regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, women choosing extended-cycle regimens should be aware of potential breakthrough bleeding in early cycles, but they should be reassured that this decreases over time and does not represent a decrease in contraceptive efficacy. In addition, the bleeding is not associated with an increased risk of endometrial hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term safety of continuous regimens has not been established. However, return of menses and fertility after stopping oral contraceptives appears to be normal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523975593\">",
"    <span class=\"h2\">",
"     Oral contraceptive with folate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Folate supplementation is currently recommended for all women with reproductive potential to prevent neural tube defects. A combination tablet containing an oral contraceptive (20 mcg ethinyl",
"    <span class=\"nowrap\">",
"     estradiol/3",
"    </span>",
"    mg drospirenone) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    (451 mcg levomefolate) is available [",
"    <a class=\"abstract\" href=\"UTD.htm?18/5/18522/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=see_link&amp;anchor=H11#H11\">",
"     \"Folic acid for prevention of neural tube defects\", section on 'Primary prevention in low risk women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Contraceptive patch and vaginal ring",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transdermal contraceptive patch (Ortho Evra) is a newer method for providing hormonal contraception. Ortho Evra patches deliver 20 mcg of ethinyl estradiol and 150 mcg of norelgestromin daily. The patch is changed once a week for three weeks, followed by one week that is patch-free. A contraceptive ring is also available (NuvaRing, which delivers 15 mcg ethinyl estradiol and 120 mcg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    daily) and is worn intravaginally for three weeks of each four-week cycle.",
"   </p>",
"   <p>",
"    Concerns have been raised about a possible excess risk of thromboembolism with the patch compared with oral contraceptives. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41127?source=see_link\">",
"     \"Transdermal contraceptive patch\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patch, vaginal ring, and other hormonal methods of contraception (including injectables, implants, and intrauterine devices) are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41127?source=see_link\">",
"     \"Transdermal contraceptive patch\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18707?source=see_link\">",
"       \"Patient information: Hormonal birth control (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=see_link\">",
"       \"Patient information: Choosing birth control (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"       \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"       \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"       \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral contraceptives (OCs) are a reliable form of contraception and have noncontraceptive benefits, as well. Furthermore, the decrease in both estrogen and progestin content in the last decade has led to a reduction in both side effects and cardiovascular complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While OCs have several mechanisms of action, the most important mechanism for providing contraception is estrogen-induced inhibition of the midcycle LH surge, so that ovulation does not occur. Another potential mechanism of contraceptive action is suppression of gonadotropin secretion during the follicular phase of the cycle, thereby preventing follicular maturation. However, a substantial number of women develop follicles while taking an OC that contains 20 to 35 mcg of ethinyl estradiol. Progestin-related mechanisms include effects on the endometrium, rendering it less suitable for implantation, and alterations in cervical mucus, which becomes less permeable to penetration by sperm. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanisms of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      OCs can be started at any time during the cycle. The preferred approach is the Quick Start method in which the woman begins taking OCs on the day that she is given the prescription, as long as pregnancy is reasonably excluded. An alternative is the Sunday Start approach where the woman starts the pill on the first Sunday after her period begins. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Initiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are a number of medical conditions that represent an unacceptable health risk for combined estrogen-progestin oral contraceptive use. The World Health Organization has published medical eligibility criteria (tables) for contraceptive use; the Centers for Disease Control (CDC) modified the tables in 2010. (See",
"      <a class=\"local\" href=\"#H175457713\">",
"       'World Health Organization tables'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H175457720\">",
"       'CDC tables'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Missed pills (particularly if the missed pills are at the beginning of the pill pack) are a common cause of contraceptive failure. We suggest that back-up contraception be used for seven days after two missed pills, regardless of dose (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Missed pills'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The metabolism of OCs is accelerated by any drug that increases liver microsomal enzyme activity such as many of the anticonvulsant drugs, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      . As a result, the contraceptive efficacy of an OC is likely to be decreased in women taking these drugs. In contrast, the metabolism of OCs is",
"      <strong>",
"       not",
"      </strong>",
"      affected by antibiotics, with the exception of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several types of combination pills. Monophasic pills contain the same dose of estrogen and progestin in each of the 21 hormonally active pills. Biphasic or triphasic pills have varying doses of hormone across the cycle (usually the progestin). There are no proven advantages to the multiphasic regimens. We suggest starting with a monophasic pill (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Preparations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The estrogen component of nearly all OCs is ethinyl estradiol. Standard OCs today contain 30 to 35 mcg of ethinyl estradiol, but many pills now contain only 20 mcg. Contraceptive efficacy with the 20 mcg pills is similar to the standard dose pills, as long as compliance is good. These lower dose pills are a good option for perimenopausal women who have menopausal symptoms (hot flashes) because they also provide contraception and bleeding control. One OC containing only 10 mcg ethinyl estradiol is now available. (See",
"      <a class=\"local\" href=\"#H150022959\">",
"       'Estrogen preparation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of menopausal symptoms with hormone therapy\", section on 'Use of oral contraceptives during the menopausal transition'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most available progestins have both progestagenic and androgenic activity (",
"      <a class=\"graphic graphic_table graphicRef78782 \" href=\"UTD.htm?35/3/35900\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef87416 \" href=\"UTD.htm?23/23/23931\">",
"       table 1",
"      </a>",
"      ). A progestin with pure progestational activity would be ideal because the androgenic activity is not needed for contraception and it increases side effects and metabolic complications. However, more selective progestins have been developed; some function as androgen receptor antagonists. To date, they have no proven clinical advantages over traditional progestins, and some have been associated with a possible higher risk of venous thromboembolism. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'New progestins'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H13#H13\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Type of progestin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/1\">",
"      Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/2\">",
"      Crosignani PG, Testa G, Vegetti W, Parazzini F. Ovarian activity during regular oral contraceptive use. Contraception 1996; 54:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/3\">",
"      Baerwald AR, Olatunbosun OA, Pierson RA. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. Contraception 2004; 70:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/4\">",
"      Schwartz JL, Creinin MD, Pymar HC, Reid L. Predicting risk of ovulation in new start oral contraceptive users. Obstet Gynecol 2002; 99:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/5\">",
"      Carr BR, Parker CR Jr, Madden JD, et al. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment. J Clin Endocrinol Metab 1979; 49:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/6\">",
"      Stewart FH, Harper CC, Ellertson CE, et al. Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence. JAMA 2001; 285:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/7\">",
"      Foster DG, Parvataneni R, de Bocanegra HT, et al. Number of oral contraceptive pill packages dispensed, method continuation, and costs. Obstet Gynecol 2006; 108:1107.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Medical eligibility criteria for contraceptive use. Fourth edition, 2009. file://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf (Accessed on June 08, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition. Early release - May 28, 2010. file://www.cdc.gov/mmwr/preview/mmwrhtml/rr59e0528a1.htm (Accessed on May 28, 2010).",
"    </li>",
"    <li>",
"     World Health Organization. Selected Practice Recommendations for Contraceptive Use, 2nd, WHO, Geneva, Switzerland 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/11\">",
"      Mansour D, Fraser IS. Missed contraceptive pills and the critical pill-free interval. Lancet 2005; 365:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/12\">",
"      Mansour D. Revision of the 'missed pill' rules. J Fam Plann Reprod Health Care 2011; 37:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/13\">",
"      Holt VL, Scholes D, Wicklund KG, et al. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005; 105:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/14\">",
"      Brunner Huber LR, Hogue CJ, Stein AD, et al. Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina. Ann Epidemiol 2006; 16:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/15\">",
"      Brunner Huber LR, Toth JL. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am J Epidemiol 2007; 166:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/16\">",
"      Lopez LM, Grimes DA, Chen-Mok M, et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev 2010; :CD008452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/17\">",
"      Burkman RT, Fisher AC, Wan GJ, et al. Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. Contraception 2009; 79:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/18\">",
"      Westhoff CL, Torgal AH, Mayeda ER, et al. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial. Obstet Gynecol 2010; 116:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/19\">",
"      ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 2010; 115:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/20\">",
"      Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/21\">",
"      Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/22\">",
"      Grimes DA, Jones LB, Lopez LM, Schulz KF. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev 2009; :CD006134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/23\">",
"      Barditch-Crovo P, Trapnell CB, Ette E, et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther 1999; 65:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/24\">",
"      Crawford P, Chadwick DJ, Martin C, et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990; 30:892.",
"     </a>",
"    </li>",
"    <li>",
"     Contraceptive Technology Update June 2004; 25:61.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/26\">",
"      Wilbur K, Ensom MH. Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. Clin Pharmacokinet 2000; 38:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/27\">",
"      Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 2007; 48:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/28\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/29\">",
"      Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol 2002; 46:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/30\">",
"      Weaver K, Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review. Contraception 1999; 59:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/31\">",
"      Dickinson BD, Altman RD, Nielsen NH, et al. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001; 98:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/32\">",
"      From the Food and Drug Administration. JAMA 2000; 283:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/33\">",
"      Verhoeven CH, van den Heuvel MW, Mulders TM, Dieben TO. The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. Contraception 2004; 69:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/34\">",
"      Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/35\">",
"      Pfrunder A, Schiesser M, Gerber S, et al. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003; 56:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/36\">",
"      Hall SD, Wang Z, Huang SM, et al. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 2003; 74:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/37\">",
"      Hilbert J, Messig M, Kuye O, Friedman H. Evaluation of interaction between fluconazole and an oral contraceptive in healthy women. Obstet Gynecol 2001; 98:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/38\">",
"      Schubert W, Cullberg G, Edgar B, Hedner T. Inhibition of 17 beta-estradiol metabolism by grapefruit juice in ovariectomized women. Maturitas 1994; 20:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/39\">",
"      Weber A, J&auml;ger R, B&ouml;rner A, et al. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 1996; 53:41.",
"     </a>",
"    </li>",
"    <li>",
"     The Medical Letter 2007; 49:20.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/41\">",
"      Rowan JP. \"Estrophasic\" dosing: A new concept in oral contraceptive therapy. Am J Obstet Gynecol 1999; 180:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/42\">",
"      van Vliet HA, Grimes DA, Lopez LM, et al. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006; :CD003553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/43\">",
"      Jensen JT. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Expert Opin Pharmacother 2010; 11:1147.",
"     </a>",
"    </li>",
"    <li>",
"     \"The Pink Sheet\" 2002; 64:24.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/45\">",
"      Gallo MF, Nanda K, Grimes DA, Schulz KF. 20 mcg versus &gt;20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; :CD003989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/46\">",
"      Kaunitz AM. Clinical practice. Hormonal contraception in women of older reproductive age. N Engl J Med 2008; 358:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/47\">",
"      Bl&uuml;mel JE, Castelo-Branco C, Binfa L, et al. A scheme of combined oral contraceptives for women more than 40 years old. Menopause 2001; 8:286.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.wcrx.com/pdfs/pi/pi_loloestrinfe.pdf. (Accessed on February 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/49\">",
"      Phillips A, Hahn DW, McGuire JL. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity. Am J Obstet Gynecol 1992; 167:1191.",
"     </a>",
"    </li>",
"    <li>",
"     Pharmacology of the Contraceptive Steroids, Goldzeiher JW, Fotherby K (Eds), Raven Press, New York 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/51\">",
"      Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstet Gynecol 1993; 81:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/52\">",
"      Vandenbroucke JP, Rosendaal FR. End of the line for \"third-generation-pill\" controversy? Lancet 1997; 349:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/53\">",
"      Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/54\">",
"      Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006; 12:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/55\">",
"      Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/56\">",
"      van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/57\">",
"      Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004; 89:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/58\">",
"      Loughlin J, Seeger JD, Eng PM, et al. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. Contraception 2008; 78:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/59\">",
"      Sch&uuml;tt B, Kunz M, Blode H. Coadministration of estradiol/drospirenone and indomethacin does not cause hyperkalemia in healthy postmenopausal women: a randomized open-label crossover study. J Clin Pharmacol 2007; 47:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/60\">",
"      Mona Eng P, Seeger JD, Loughlin J, et al. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes. Contraception 2007; 75:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/61\">",
"      Bachmann G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 2004; 70:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/62\">",
"      Edelman A. Menstrual nirvana: amenorrhea through the use of continuous oral contraceptives. Curr Womens Health Rep 2002; 2:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/63\">",
"      Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006; 74:439.",
"     </a>",
"    </li>",
"    <li>",
"     The Pink Sheet 2007; 69:8.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/65\">",
"      Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003; 101:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/66\">",
"      Edelman AB, Gallo MF, Jensen JT, et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; :CD004695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/67\">",
"      Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/68\">",
"      Legro RS, Pauli JG, Kunselman AR, et al. Effects of continuous versus cyclical oral contraception: a randomized controlled trial. J Clin Endocrinol Metab 2008; 93:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/69\">",
"      Johnson JV, Grubb GS, Constantine GD. Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 micro g/ethinyl estradiol 20 micro g. Contraception 2007; 75:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/70\">",
"      Davis AR, Kroll R, Soltes B, et al. Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive. Fertil Steril 2008; 89:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/5/18522/abstract/71\">",
"      Drugs for female sexual dysfunction. Med Lett Drugs Ther 2010; 52:100.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7398 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18522=[""].join("\n");
var outline_f18_5_18522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Use in hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Use in other disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Screening requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Initiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3033285\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175457713\">",
"      - World Health Organization tables",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175457720\">",
"      - CDC tables",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Missed pills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effect of weight",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NONCONTRACEPTIVE BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Menstrual cycle disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gynecologic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cancer risk reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ovarian cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      USE DURING LACTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150022643\">",
"      Mono- versus multiphasic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150022959\">",
"      Estrogen preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H150022978\">",
"      - Type",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H150022985\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      20 to 25 mcg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H627283998\">",
"      Perimenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H150023028\">",
"      10 mcg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      New progestins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Antiandrogenic progestins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Shorter pill-free interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Continuous pill",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523975593\">",
"      Oral contraceptive with folate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Contraceptive patch and vaginal ring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7398\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7398|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/23/23931\" title=\"table 1\">",
"      Classification progestins in combined OC pills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/3/35900\" title=\"table 2\">",
"      Activity of OC preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/51/21311\" title=\"table 3\">",
"      WHO MEC Personal characteristics and reproductive history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/25/40350\" title=\"table 4\">",
"      WHO criteria for contraceptive use in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/61/37853\" title=\"table 5\">",
"      WHO MEC for neurologic conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/1/1052\" title=\"table 6\">",
"      WHO MEC for Depressive disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/28/34255\" title=\"table 7\">",
"      WHO MEC for reproductive tract infections and disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/20/39245\" title=\"table 8\">",
"      WHO MEC for women with HIV AIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/40/5774\" title=\"table 9\">",
"      WHO MEC for gastrointestinal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/49/23324\" title=\"table 10\">",
"      WHO MEC for thalassemia and sickle cell disease and anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/34/20013\" title=\"table 11\">",
"      WHO MEC for patients with endocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/54/37741\" title=\"table 12\">",
"      WHO MEC for potential drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/14/42220\" title=\"table 13\">",
"      WHO MEC for patients with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/13/12506\" title=\"table 14\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/56/13197\" title=\"table 15\">",
"      Pregnancy rate during first year of contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/59/11184\" title=\"table 16\">",
"      Estrogen and progestin types and doses in hormonal contraceptive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/15/7419\" title=\"table 17\">",
"      Indications for progestin only contraception",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4233?source=related_link\">",
"      Contraception counseling for obese women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35433?source=related_link\">",
"      Estrogen-associated migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=related_link\">",
"      Folic acid for prevention of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=related_link\">",
"      HIV and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=related_link\">",
"      Hormonal contraception for suppression of menstruation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44599?source=related_link\">",
"      Hormonal therapy for women with acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=related_link\">",
"      Overview of the treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=related_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=related_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18707?source=related_link\">",
"      Patient information: Hormonal birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=related_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=related_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=related_link\">",
"      Progestin-only pills (minipills) for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41127?source=related_link\">",
"      Transdermal contraceptive patch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=related_link\">",
"      Treatment of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=related_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=related_link\">",
"      Treatment of premenstrual syndrome and premenstrual dysphoric disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28233?source=related_link\">",
"      Treatment of primary dysmenorrhea in adult women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/17/27928?source=related_link\">",
"      Use of combination estrogen-progestin contraceptives in the treatment of hyperandrogenism and hirsutism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_5_18523="Initial ventilator settings";
var content_f18_5_18523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial ventilator settings in children with status asthmaticus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended initial setting",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum recommended setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tidal volume",
"       </td>",
"       <td>",
"        8-10 ml/kg",
"       </td>",
"       <td>",
"        12 ml/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory rate",
"       </td>",
"       <td>",
"        8-12 breaths/min",
"       </td>",
"       <td>",
"        16 breaths/min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inspiratory time",
"       </td>",
"       <td>",
"        0.75- 1 second",
"       </td>",
"       <td>",
"        1.5 seconds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I: E ratio",
"       </td>",
"       <td>",
"        1:3 - 1:5",
"       </td>",
"       <td>",
"        &gt;1:3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inspiratory flow",
"       </td>",
"       <td>",
"        4-10 liters/kg/min",
"       </td>",
"       <td>",
"        4-10 liters/kg/min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minute ventilation",
"       </td>",
"       <td>",
"        &lt;115 ml/kg/min",
"       </td>",
"       <td>",
"        &lt;115 ml/kg/min",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18523=[""].join("\n");
var outline_f18_5_18523=null;
var title_f18_5_18524="Newer antiplatelet ASGE";
var content_f18_5_18524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ASGE recommendations regarding newer antiplatelet agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Acute GI hemorrhage in the patient taking clopidogrel or ticlodipine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clopidogrel or ticlodipine should be discontinued. The decision to reverse the antiplatelet effect, risking ischemic consequences, must be weighed against the risk of continued bleeding by maintaining the state of impaired platelet aggregation. If quick reversal is required, platelet transfusion may be appropriate.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Elective endoscopic procedures in the patient taking clopidogrel or ticlopidine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A decision regarding discontinuation of therapy before endoscopy has to be weighed against the patient's risk for developing an adverse ischemic event, including coronary stent occlusion. Endoscopic procedures previously have been categorized as low-risk or high-risk for bleeding (table).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Low-risk procedures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       No adjustments in antiplatelet regimen need to be made.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       High-risk procedures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Whether to discontinue these agents has not been determined. If discontinued, when possible, they should be stopped 7 to 10 days before the procedure. Because of the slow onset of action, it may be appropriate to restart the drug the following day. In patients who receive clopidogrel plus aspirin, consider reversion to a single agent (preferably aspirin) before elective endoscopy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Patients taking dipyridamole",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       In the absence of a preexisting bleeding disorder, endoscopic procedures may be performed in patients who take dipyridamole or combination dipyridamole-aspirin in standard doses. However, the safety in patients undergoing high-risk procedures is unknown.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Patients taking a Gp IIb/IIIa inhibitor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Patients being considered for elective endoscopy are not typically exposed to this class of drug. For patients requiring emergency endoscopy for acute GI hemorrhage, the GP II/b/IIIa infusion should be discontinued. Eptifibatide and tirofiban have a relatively short duration, of about 4 hours of action, whereas abciximab may last up to 24 hours. Transfusion of platelets or use of DDAVP may play a role in the setting of major bleeding.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE). Gastrointest Endosc 2005; 61:189.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18524=[""].join("\n");
var outline_f18_5_18524=null;
var title_f18_5_18525="MRP 2 gene mutations";
var content_f18_5_18525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 599px\">",
"   <div class=\"ttl\">",
"    Map of mutations detected in the MRP2 gene in patients with Dubin-Johnson syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 579px; height: 162px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The vertical boxes represent the exons of the MRP2 gene. The numbers below the boxes mark the exons. 5' UTR and 3' UTR are the 5' and 3' untranslated regions. The inverted pointers labeled with alphabets, \"a\" through \"h\", above the exons denote all the mutations detected to the date in this gene.",
"    <div class=\"footnotes\">",
"     (a) Exon-13:1669-1815del [42]. (b) IVS15, +2T&gt;C [43]. (c) Exon-18:2302C&gt;T (R368W) [42]. (d) Exon:18:2272-2439del [42]. (e) Exon 23: 3196 C&gt;T (R1066X) [41]. (f)Exon-25:3449G&gt;A (R1150H) [44] (g) Exon-25:3517A&gt;T (I1173F) [44] (h) Exon-30:4175-4180del [39].",
"    </div>",
"    <div class=\"reference\">",
"     Note: Nomenclature of mutations in accordance with den Dunnen, JT, Antonarakis, SE. Hum Mutat 2000; 15:7.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18525=[""].join("\n");
var outline_f18_5_18525=null;
var title_f18_5_18526="Schematic continuous murmurs";
var content_f18_5_18526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Schematic of continuous murmurs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 274px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Continuous murmurs begin in systole and continue without interruption through the second heart sound (S2) into all or part of diastole. The continuous murmers shown here are aortopulmonary, systemic arterial, and systemic venous. A holosystolic murmur (SM) followed by a holodiastolic murmur (DM) represents two separate murmurs, not one continuous murmur.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from Heart Disease: A Textbook of Cardiovascular Medicine, Braunwald E (Ed), WB Saunders, Philadelphia, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18526=[""].join("\n");
var outline_f18_5_18526=null;
var title_f18_5_18527="DHEAS pubic hair develop";
var content_f18_5_18527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Serum DHEA-S concentrations in relation to pubic hair development",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 407px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A rise in DHEA-S levels at about six years of age is the major indicator of adrenarche. The upper limit for boys rises above that of girls during the late prepubertal years. Pubertal groups are subcategorized by pubic hair developmental stages. Among boys with premature pubarche, some have high serum DHEA-S concentrations for age (circles), some do not (diamonds). Serum DHEA-S concentrations are also shown for older boys who have pubarche before gonadarche (small rectangles); similar concentrations are often not associated with pubarche in normal subjects (pubertal stage I).",
"    <div class=\"footnotes\">",
"     DHEA-S: dehydroepiandrosterone sulfate.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Rosenfield RL, Rich BH, Lucky AW. Adrenarche as a cause of benign pseudopuberty in boys. J Pediatr 1982; 101:1005. Copyright &copy; 1982 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_5_18527=[""].join("\n");
var outline_f18_5_18527=null;
